Raymond F. Schinazi

Raymond F. Schinazi's AcademicInfluence.com Rankings

Raymond F. Schinazi

Medical

#604

World Rank

#810

Historical Rank

#224

USA Rank

Pediatrics

#18

World Rank

#26

Historical Rank

#11

USA Rank

medical Degrees

Download Badge

Medical

Why Is Raymond F. Schinazi Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Raymond F. Schinazi is an American organic medicinal chemist at Emory University with expertise in antiviral agents, pharmacology, and biotechnology. His research focuses on developing treatments for infections caused by human immunodeficiency virus , hepatitis B , hepatitis C , herpes, dengue fever, zika, chikungunya, and other emerging viruses. These treatment options include antiviral agents as well as synthetic, biochemical, pharmacological and molecular genetic approaches, including molecular modeling and gene therapy.

(See a Problem?)

Raymond F. Schinazi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Polyoxometalates in Medicine. (1998) (1536)
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. (2000) (959)
Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry. (2009) (655)
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. (1991) (496)
Mutations in Retroviral Genes Associated with Drug Resistance (1996) (441)
Zika Virus Infects Human Placental Macrophages. (2016) (405)
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides (1993) (379)
Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs (2014) (356)
Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir (2008) (347)
Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. (2001) (316)
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (1992) (289)
In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. (1997) (274)
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. (2001) (272)
Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region (2001) (251)
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene (1997) (249)
HCV direct‐acting antiviral agents: the best interferon‐free combinations (2014) (243)
Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure (2015) (241)
Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes (1992) (237)
Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus. (1987) (235)
COVID-19: Discovery, diagnostics and drug development (2020) (233)
Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. (1999) (222)
Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. (1992) (220)
Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. (2016) (207)
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. (2015) (206)
Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection (2001) (197)
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. (2001) (188)
Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene (1993) (180)
Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. (2005) (177)
Viral Sanctuaries during Highly Active Antiretroviral Therapy in a Nonhuman Primate Model for AIDS (2009) (166)
Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1 (1990) (164)
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells (2021) (161)
Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture (2003) (160)
Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. (1990) (157)
Synthesis and quantitative structure-activity relationship analysis of 2-(aryl or heteroaryl)quinolin-4-amines, a new class of anti-HIV-1 agents. (1991) (146)
Synthesis of enantiomerically pure (2'R,5'S)-(-)-1-(2-hydroxymethyloxathiolan-5-yl)cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV) (1992) (145)
Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases. (2004) (143)
Anti-HIV-1 activity, toxicity, and stability studies of representative structural families of polyoxometalates. (1990) (140)
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template (2021) (135)
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. (2005) (134)
Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease, Atlanta, Georgia, USA, 2020 (2020) (130)
Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon (2008) (126)
Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. (1995) (125)
Antiviral Activities and Cellular Toxicities of Modified 2′,3′-Dideoxy-2′,3′-Didehydrocytidine Analogues (2002) (125)
New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge. (2003) (123)
Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques (2020) (120)
Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure? (2018) (118)
Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2′-Deoxynucleoside Triphosphates (2000) (118)
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals (2014) (117)
Phenolics with antiviral activity from Millettia Erythrocalyx and Artocarpus Lakoocha (2005) (116)
Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice (1982) (114)
In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of oxathiolanyl and dioxolanyl nucleoside analogues (1991) (114)
Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity. (1992) (113)
Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. (2008) (113)
Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro (1994) (112)
Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells. (1989) (108)
Pharmacokinetics of a water-soluble fullerene in rats (1996) (108)
Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. (1991) (107)
Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents. (1993) (106)
Insights into HIV chemotherapy. (1992) (105)
Mechanism of Activation of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase (2007) (105)
In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β-d-Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine (2000) (100)
Best strategies for global HCV eradication (2013) (99)
Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol (1989) (99)
Inhibition of Hepatitis C Replicon RNA Synthesis by β-D-2′-deoxy-2′-fluoro-2′-C-Methylcytidine: A Specific Inhibitor of Hepatitis C Virus Replication (2006) (97)
Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). (1988) (97)
Preclinical Characterization of GLS4, an Inhibitor of Hepatitis B Virus Core Particle Assembly (2013) (96)
Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro. (1987) (96)
Monitoring Medication Adherence by Unannounced Pill Counts Conducted by Telephone: Reliability and Criterion-Related Validity (2008) (96)
Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. (2017) (93)
Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. (1993) (92)
Batzelladine alkaloids from the caribbean sponge Monanchora unguifera and the significant activities against HIV-1 and AIDS opportunistic infectious pathogens (2007) (91)
Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity (1988) (90)
Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro (1994) (88)
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro (1989) (87)
Antiretroviral Therapy in Macrophages: Implication for HIV Eradication (2009) (87)
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019 (2020) (86)
Ribonucleoside Triphosphates as Substrate of Human Immunodeficiency Virus Type 1 Reverse Transcriptase in Human Macrophages* (2010) (86)
Synthesis of 5-(dihydroxyboryl)-2'-deoxyuridine and related boron-containing pyrimidines (1985) (85)
Human Herpesvirus 8 Open Reading Frame 21 Is a Thymidine and Thymidylate Kinase of Narrow Substrate Specificity That Efficiently Phosphorylates Zidovudine but Not Ganciclovir (2000) (84)
1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. (1993) (84)
HUMAN IMMUNODEFICIENCY VIRUS ISOLATED FROM AMNIOTIC FLUID (1987) (84)
Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. (2011) (83)
Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. (2003) (81)
Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. (2007) (81)
Synthesis of Dihydroisoxazole Nucleoside and Nucleotide Analogs. (1997) (81)
Nonhuman Primate Models for Evaluation of AIDS Therapy a (1990) (80)
Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. (1990) (78)
Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. (1988) (77)
Mechanism of Action of 1-β-d-2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1-β-d-Dioxolane Guanosine (2001) (77)
Manadomanzamines A and B: a novel alkaloid ring system with potent activity against mycobacteria and HIV-1. (2003) (77)
Correlation between preferred sugar ring conformation and activity of nucleoside analogues against human immunodeficiency virus. (1989) (75)
L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. (1993) (73)
Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase (2004) (73)
Ruxolitinib and Tofacitinib Are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation In Vitro (2014) (73)
Preparation of ribavirin analogues by copper- and ruthenium-catalyzed azide-alkyne 1,3-dipolar cycloaddition. (2008) (72)
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. (2016) (72)
In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase (2005) (72)
HCV drug discovery aimed at viral eradication (2010) (71)
Potent anti-HIV and anti-HBV activities of (−)-L-β-dioxolane-C and (+)-L-β-dioxolane-T and their asymmetric syntheses. (1992) (71)
Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors (2017) (70)
Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites (2003) (70)
Towards new boron carriers for boron neutron capture therapy: metallacarboranes and their nucleoside conjugates. (2005) (69)
SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. (2016) (69)
Therapies for Viral Hepatitis (1998) (69)
Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC) and related compounds (1992) (69)
Chutes and ladders in hepatitis C nucleoside drug development. (2014) (69)
Antiretroviral Monocyte Efficacy Score Linked to Cognitive Impairment in Hiv (2012) (68)
Nucleic acids and nucleosides containing carboranes (1999) (68)
Role of Marine Natural Products in the Genesis of Antiviral Agents. (2015) (68)
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates (1995) (68)
Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. (1997) (68)
Anti-HIV-1 activity and cellular pharmacology of various analogs of gossypol. (1993) (68)
Predicting Zika virus structural biology: Challenges and opportunities for intervention (2015) (67)
Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1 (2005) (67)
Enantiomeric synthesis of (+)-BCH-189 [(+)-(2S,5R)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine] from D-mannose and its anti-HIV activity (1991) (67)
Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs. (1997) (67)
All‐oral, interferon‐free treatment for chronic hepatitis C: cost‐effectiveness analyses (2013) (67)
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. (2004) (66)
Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. (2007) (65)
Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs (1994) (65)
Synthesis, characterization, and biological activity of a new potent class of anti-HIV agents, the peroxoniobium-substituted heteropolytungstates. (1994) (64)
The human herpesviruses: an interdisciplinary perspective. (1981) (64)
Enantiomeric synthesis of D- and L-cyclopentenyl nucleosides and their antiviral activity against HIV and West Nile virus. (2001) (63)
Solid-state conformation of anti-human immunodeficiency virus type-1 agents: Crystal structures of three 3'-azido-3'-deoxythymidine analogs (1988) (63)
Approaches to hepatitis C treatment and cure using NS5A inhibitors (2014) (63)
Modification at the C9 position of the marine natural product isoaaptamine and the impact on HIV-1, mycobacterial, and tumor cell activity. (2006) (63)
Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon. (2003) (62)
Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2′-Deoxy-2′-Fluorocytidine (2004) (62)
Treatment as prevention and cure towards global eradication of hepatitis C virus. (2013) (62)
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. (2001) (62)
Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. (1991) (62)
YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine (2003) (61)
Towards HBV curative therapies (2018) (61)
A research agenda for curing chronic hepatitis B virus infection (2018) (61)
Mechanistic studies show that (−)‐FTC‐TP is a better inhibitor of HIV‐1 reverse transcriptase than 3TC‐TP (1999) (60)
Synthesis, characterization, and anti-human immunodeficiency virus activity of water-soluble salts of polyoxotungstate anions with covalently attached organic groups. (1992) (60)
Virulence and Reduced Fitness of Simian Immunodeficiency Virus with the M184V Mutation in Reverse Transcriptase (2002) (60)
A COMPLETELY DIASTEREOSELECTIVE ELECTROPHILIC FLUORINATION OF A CHIRAL, NONCARBOHYDRATE SUGAR RING PRECURSOR : APPLICATION TO THE SYNTHESIS OF SEVERAL NOVEL 2'-FLUORONUCLEOSIDES (1998) (59)
Antiviral Activity of Nucleoside Analogues against Norovirus (2012) (59)
Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase* (2008) (58)
Significance of endangered and threatened plant natural products in the control of human disease (2013) (57)
5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens (2005) (56)
Effect of Oral Administration of Emtricitabine on Woodchuck Hepatitis Virus Replication in Chronically Infected Woodchucks (2000) (56)
Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. (2006) (55)
Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH)--the major therapeutic target. (2004) (55)
Food Insufficiency and Medication Adherence Among People Living with HIV/AIDS in Urban and Peri-Urban Settings (2011) (55)
Randomized Clinical Trial of HIV Treatment Adherence Counseling Interventions for People Living With HIV and Limited Health Literacy (2013) (55)
Synthesis and anti-HIV and anti-HBV activities of 2'-fluoro-2', 3'-unsaturated L-nucleosides. (1999) (54)
DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants (2002) (54)
Antiviral and Anticancer Optimization Studies of the DNA‐binding Marine Natural Product Aaptamine (2008) (53)
Asymmetric synthesis of enantiomerically pure (−)-(1′R,4′R)-dioxolane-thymine and its anti-HIV activity. (1991) (53)
Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus (1983) (53)
Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. (2006) (53)
Marine natural products as lead anti-HIV agents. (2003) (53)
Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome (2010) (52)
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model (2016) (52)
Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate (1989) (52)
Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys (1991) (52)
Anti-infective discorhabdins from a deep-water alaskan sponge of the genus Latrunculia. (2010) (52)
Anti-HIV-1 and cytotoxicity studies of piperidyl-thienyl chalcones and their 2-pyrazoline derivatives (2012) (52)
Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. (1996) (51)
Efficient synthesis of various acycloalkenyl derivatives of pyrimidine using cross-metathesis and Pd(0) methodologies (2005) (50)
Synthesis and antiviral activity of novel acyclic nucleosides in the 5-alkynyl- and 6-alkylfuro[2,3-d]pyrimidine series. (2005) (50)
Advances in nucleoside monophosphate prodrugs as anti-HCV agents (2010) (50)
Combined Antiviral Effect of Interferon and Acyclovir on Herpes Simplex Virus Types 1 and 2 (1981) (49)
Long-Term Exposure to AZT, but not d4T, Increases Endothelial Cell Oxidative Stress and Mitochondrial Dysfunction (2009) (49)
Antiviral beta-L-nucleosides specific for hepatitis B virus infection. (2001) (49)
Mutations in RT and Protease III -93 NOV 95 Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance (1996) (49)
Anti-human immunodeficiency and anti-hepatitis B virus activities of β-l-2′,3′-dideoxy purine nucleosides (1996) (49)
A Stereochemical Rationale for the Activity of Anti-HIV Nucleosides (1990) (48)
Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase (2021) (48)
Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells. (1992) (48)
Anti-human immunodeficiency virus activity and cytotoxicity of derivatized buckminsterfullerenes (1996) (48)
Use of dietary supplements among people living with HIV/AIDS is associated with vulnerability to medical misinformation on the internet (2012) (48)
Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys (1990) (48)
Structure-activity relationships of beta-D-(2S,5R)- and alpha-D-(2S,5S)-1,3-oxathiolanyl nucleosides as potential anti-HIV agents. (1993) (47)
An Overview of the Further Evaluation of Penciclovir against Herpes Simplex Virus and Varicella-Zoster Virus in Cell Culture Highlighting Contrasts with Acyclovir (1993) (47)
Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys (1992) (47)
Facile purification of honokiol and its antiviral and cytotoxic properties. (2006) (47)
Synthesis, Structure−Activity Relationships, and Drug Resistance of β-d-3‘-Fluoro-2‘,3‘-Unsaturated Nucleosides as Anti-HIV Agents (2004) (47)
Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis (1986) (47)
Porphyrins as Agents against the Human Immunodeficiency Virus a (1990) (47)
Characterization of β-d-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus (2017) (47)
Synthesis and biological activities of 5-(hydroxymethyl, azidomethyl, or aminomethyl)-2'-deoxyuridine and related 5'-substituted analogues. (1980) (46)
Synthesis and biological evaluation of 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. (1999) (46)
Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. (2002) (46)
3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. (1990) (46)
Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents. (1985) (46)
Anti-HIV Host Factor SAMHD1 Regulates Viral Sensitivity to Nucleoside Reverse Transcriptase Inhibitors via Modulation of Cellular Deoxyribonucleoside Triphosphate (dNTP) Levels* (2013) (45)
Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. (1986) (45)
Acyclic analogues of 3'-azido-3'-deoxythymidine as potential antiviral agents. Nucleoside synthesis by Michael addition. (1989) (45)
The 3′-Azido Group Is Not the Primary Determinant of 3′-Azido-3′-deoxythymidine (AZT) Responsible for the Excision Phenotype of AZT-resistant HIV-1* (2005) (45)
HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids. (1992) (44)
Structure-activity relationships of 2'-fluoro-2',3'-unsaturated D-nucleosides as anti-HIV-1 agents. (2002) (44)
Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques (2018) (44)
Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1 (2004) (43)
Synthesis and antiviral activity of oxaselenolane nucleosides. (2000) (43)
Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase. (1996) (43)
Human immunodeficiency virus in semen and plasma: investigation of sexual transmission risk behavioral correlates. (2001) (43)
Substrates and Inhibitors of SAMHD1 (2017) (43)
Cellular pharmacology and biological activity of 5-carboranyl-2'-deoxyuridine. (1994) (43)
Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition (2014) (43)
Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy (1999) (43)
Phenylselenenyl- and phenylthio-substituted pyrimidines as inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase. (1993) (42)
Simultaneous quantification of intracellular natural and antiretroviral nucleosides and nucleotides by liquid chromatography-tandem mass spectrometry. (2010) (42)
Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro (1993) (42)
The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents (2012) (42)
Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1 (1988) (42)
Synthesis and anti-viral activity of a series of d- and l-2'-deoxy-2'-fluororibonucleosides in the subgenomic HCV replicon system. (2005) (42)
Structure-activity relationships of 2'-deoxy-2',2'-difluoro-L-erythro-pentofuranosyl nucleosides. (1997) (41)
Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration (2021) (41)
Efficient Pd(0)-catalyzed synthesis of 1,2,3-triazolo-3′-deoxycarbanucleosides and their analogues (2005) (41)
Pre-steady-state Kinetic Studies Establish Entecavir 5′-Triphosphate as a Substrate for HIV-1 Reverse Transcriptase* (2008) (41)
Competitive inhibitors of human immunodeficiency virus reverse transcriptase (1993) (40)
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572 (2010) (40)
Boron Containing Pyrimidines, Nucleosides, and Oligonucleotides for Neutron Capture Therapy (1994) (40)
In vitro Antimyxovirus and Anti-Human Immunodeficiency Virus Activities of Polyoxometalates (1995) (40)
Aromatic amino acid phosphoramidate di- and triesters of 3′-azido-3′-deoxythymidine (AZT) are non-toxic inhibitors of HIV-1 replication (1995) (40)
Correlation of Molecular Conformation and Activity of Reverse Transcriptase Inhibitors a (1990) (39)
Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice. (1989) (39)
Agonist of RORA Attenuates Non-Alcoholic Fatty Liver Progression in Mice via Upregulation of microRNA 122. (2020) (39)
An Efficient Route to beta-D-Isoxazolidinyl Nucleosides via Diastereoselective Michael Addition of Hydroxylamine to Unsaturated Esters. (1997) (38)
HIV-1 Resistance Profile of the Novel Nucleoside Reverse Transcriptase Inhibitor β-D-2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine (Reverset™) (2003) (38)
Enhanced Antiviral Benefit of Combination Therapy with Lamivudine and Alpha Interferon against WHV Replication in Chronic Carrier Woodchucks (1999) (38)
Selenium nucleophiles for the preparation of antiviral nucleosides (1991) (38)
Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020 (2020) (38)
Mololipids, a new series of anti-HIV bromotyramine-derived compounds from a sponge of the order verongida. (2000) (37)
Cell-Based and Animal Models for Hepatitis B and C Viruses (1999) (37)
dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages (2014) (37)
l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance. (2003) (37)
Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks (1996) (37)
Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species. (1990) (36)
Antiviral iodinated pyrimidine deoxyribonucleosides: 5-iodo-2'-deoxyuridine; 5-iodo-2'-deoxycytidine; 5-iodo-5'-amino-2',5'-dideoxyuridine. (1979) (36)
Monthly Unannounced Pill Counts for Monitoring HIV Treatment Adherence: Tests for Self-Monitoring and Reactivity Effects (2010) (36)
Synthesis and structure-activity relationships of 6-substituted 2',3'-dideoxypurine nucleosides as potential anti-human immunodeficiency virus agents. (1990) (35)
Asymmetric synthesis and antiviral activities of L-carbocyclic 2', 3'-didehydro-2',3'-dideoxy and 2',3'-dideoxy nucleosides. (1999) (35)
Effects of modifications in the pentose moiety and conformational changes on the binding of nucleoside ligands to uridine phosphorylase from Toxoplasma gondii. (1996) (35)
Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. (2000) (35)
Randomized Factorial Trial of Phone-Delivered Support Counseling and Daily Text Message Reminders for HIV Treatment Adherence (2016) (35)
Repurposing Nucleoside Analogs for Human Coronaviruses (2020) (35)
Phenolics with Anti-HSV and Anti-HIV Activities from Artocarpus gomezianus., Mallotus pallidus., and Triphasia trifolia. (2005) (34)
Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships. (1986) (34)
Cellular Pharmacology and Potency of HIV-1 Nucleoside Analogs in Primary Human Macrophages (2012) (34)
Synthesis and properties of boron and silicon substituted uracil or 2′-deoxyuridine (1979) (34)
Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. (1994) (33)
A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro. (1996) (33)
Synthesis and in vitro anti-human immunodeficiency virus activity of artemisinin (qinghaosu)-related trioxanes (1994) (33)
Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases (1989) (33)
A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides (1997) (33)
Sexual HIV Transmission and Antiretroviral Therapy: A Prospective Cohort Study of Behavioral Risk Factors Among Men and Women Living with HIV/AIDS (2011) (33)
Combinations of 2'-C-Methylcytidine Analogues with Interferon-α2b and Triple Combination with Ribavirin in the Hepatitis C Virus Replicon System (2008) (32)
Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. (2015) (32)
SAMHD1 Functions and Human Diseases (2020) (32)
Synthesis, anti-HIV activity, and molecular mechanism of drug resistance of L-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides. (2003) (32)
Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. (2017) (32)
Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2 (1986) (32)
A Novel Point Mutation at Position 156 of Reverse Transcriptase from Feline Immunodeficiency Virus Confers Resistance to the Combination of (−)-β-2′,3′-Dideoxy-3′-Thiacytidine and 3′-Azido-3′-Deoxythymidine (1998) (32)
Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors. (2013) (31)
Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions (1994) (31)
Abundant Non-canonical dUTP Found in Primary Human Macrophages Drives Its Frequent Incorporation by HIV-1 Reverse Transcriptase* (2011) (31)
Synthesis of enantiomerically pure cyclopropyl carbocyclic nucleosides (1994) (31)
Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies. (2006) (31)
Assessment of the relative potency of emtricitabine and lamivudine. (2003) (31)
Synthesis and anti-HIV activity of D- and L-thietanose nucleosides. (2006) (31)
A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. (2010) (30)
Synthesis, biotransformation, and pharmacokinetic studies of 9-(beta-D-arabinofuranosyl)-6-azidopurine: a prodrug for ara-A designed to utilize the azide reduction pathway. (1996) (30)
Synergistic Drug Combinations in AIDS Therapy (1990) (30)
Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis (1995) (30)
In-vitro activities of paromomycin and lasalocid evaluated in combination against Cryptosporidium parvum. (1998) (30)
Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase* (2009) (30)
Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection (2020) (30)
Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. (2009) (30)
Synthesis, Structure−Activity Relationships, and Mechanism of Drug Resistance of d- and l-β-3‘-Fluoro-2‘,3‘-unsaturated-4‘-thionucleosides as Anti-HIV Agents (2004) (29)
Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ (2015) (29)
Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy (2017) (29)
Carboranyl Oligonucleotides. 2. Synthesis and Physicochemical Properties of Dodecathymidylate Containing 5-(o-Carboran-1-yl)-2'-deoxyuridine (1994) (29)
Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease. (2017) (29)
Synthesis, antiviral activity, and mechanism of drug resistance of D- and L-2',3'-didehydro-2',3'-dideoxy-2'-fluorocarbocyclic nucleosides. (2005) (28)
Antiviral methods and protocols (1999) (28)
A synthetic route to 3-(dialkylamino)phenothiazin-5-ium salts and 3,7-disubstituted derivatives containing two different amino groups (1993) (28)
Different in vitro effects of dual combinations of anti-herpes simplex virus compounds. (1982) (28)
Antiviral and antineoplastic activities of pyrimidine arabinosyl nucleosides and their 5'-amino derivatives. (1979) (27)
A Rapid Non-Culture-Based Assay for Clinical Monitoring of Phenotypic Resistance of Human Immunodeficiency Virus Type 1 to Lamivudine (3TC) (1999) (27)
Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro (2019) (27)
Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice (2019) (27)
AIDS in Children, Adolescents and Heterosexual Adults: An Interdisciplinary Approach to Prevention (1988) (27)
Site-specific Incorporation of Nucleoside Analogs by HIV-1 Reverse Transcriptase and the Template Grip Mutant P157S (2000) (26)
The polymerase L 528 M mutation cooperates with nucleotide binding-site mutations , increasing hepatitis B virus replication and drug resistance (2001) (26)
Synthesis, evaluation of anti-HIV-1 and anti-HCV activity of novel 2',3'-dideoxy-2',2'-difluoro-4'-azanucleosides. (2012) (26)
Synthesis of neplanocin F analogues as potential antiviral agents. (2006) (26)
From HCV To HBV Cure (2017) (26)
Interactions of enantiomers of 2',3'-didehydro-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. (2002) (25)
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. (2016) (25)
Synthesis of dihydropyrimidine α,γ-diketobutanoic acid derivatives targeting HIV integrase. (2015) (25)
Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys (1996) (25)
Carboranyl oligonucleotides. 1. Synthesis of thymidine(3',5')thymidine (o-carboran-1-ylmethyl)phosphonate (1993) (25)
Stereoselective Synthesis and Antiviral Activity of d-2‘,3‘-Didehydro-2‘,3‘-dideoxy-2‘-fluoro-4‘-thionucleosides (2002) (25)
Derivatives of 4‐amino‐3,6‐disulfonato‐1, 8‐naphthalimide inhibit reverse transcriptase and suppress human and feline immunodeficiency virus expression in cultured cells (1993) (24)
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms. (2015) (24)
Cell-specific antiviral activity of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC) against Marek's disease herpesvirus and turkey herpesvirus. (1984) (24)
Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. (2005) (24)
Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors. (2012) (24)
The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
Conformational Analysis of 2',3'-Didehydro-2',3'-dideoxypyrimidine Nucleosides. (1993) (24)
Biologic properties of human herpesvirus 7 strain SB. (1997) (24)
Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection. (2011) (24)
Mechanistic and Kinetic Differences between Reverse Transcriptases of Vpx Coding and Non-coding Lentiviruses* (2015) (24)
Metabolism of the Anti-Hepatitis C Virus Nucleoside β-d-N4-Hydroxycytidine in Different Liver Cells (2004) (24)
Cu(I)-Catalyzed Huisgen Azide—Alkyne 1,3-Dipolar Cycloaddition Reaction in Nucleoside, Nucleotide, and Oligonucleotide Chemistry (2010) (23)
Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells. (1995) (23)
Probing the Mechanistic Consequences of 5-Fluorine Substitution on Cytidine Nucleotide Analogue Incorporation by HIV-1 Reverse Transcriptase (2003) (23)
Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines (1994) (23)
Simian immunodeficiency virus macaque models of HIV latency (2011) (23)
Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. (2002) (23)
Pharmacokinetics of (-)-β-D-2,6-Diaminopurine Dioxolane and its Metabolite, Dioxolane Guanosine, in Woodchucks (Marmota Monax) (1996) (23)
Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop (2017) (23)
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. (2017) (23)
In-vitro anti Myxovirus Activity and Mechanism of Antiinfluenzavirus Activity of Polyoxometalates PM-504 and PM-523 (1996) (23)
2′-and/or 3Y-Deoxy-β-L-pentofuranosyl Nucleoside Derivatives: Stereospecific Synthesis and Antiviral Activities (1995) (23)
Kinetic variations between reverse transcriptases of viral protein X coding and noncoding lentiviruses (2014) (23)
SYNTHESIS AND ANTI-HIV ACTIVITY OF DIHYDROISOXAZOLE 6-CHLOROPURINE AND ADENINE (1996) (23)
Quantifying Mixed Populations of Drug-Resistant Human Immunodeficiency Virus Type 1 (2005) (23)
Enantiomeric 2',3'-dideoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell cultures. (1994) (22)
Synthesis and biological activity of 5-phenylselenenyl-substituted pyrimidine nucleosides. (1986) (22)
Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V. (2004) (22)
Infection dynamics and clinical features of cryptosporidiosis in SCID mice (1994) (22)
ANTI-HBV SPECIFIC β-L-2′-DEOXYNUCLEOSIDES (2001) (22)
Amino- and Hydroxytetraphenylporphyrins with Activity against the Human Immunodeficiency Virus (1992) (22)
Anti-hepatitis C Virus Activity of Novel β-D-2′-C-methyl-4′-azido Pyrimidine Nucleoside Phosphoramidate Prodrugs (2009) (22)
Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides (2013) (22)
3'-(1,2,3-Triazol-1-yl)-3'-deoxythymidine analogs as substrates for human and Ureaplasma parvum thymidine kinase for structure-activity investigations. (2010) (22)
Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases (1996) (22)
The synthesis and anti-hiv activity of pyrimidine dioxolanyl nucleosides (1993) (22)
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy (2020) (22)
Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis (2015) (22)
Synthesis and evaluation of non-dimeric HCV NS5A inhibitors. (2013) (22)
Jak Inhibitors Modulate Production of Replication-Competent Zika Virus in Human Hofbauer, Trophoblasts, and Neuroblastoma cells (2017) (22)
Synthesis and anti-HIV activities of 2′-deoxy-2′,2″-difluoro-β-L-ribofuranosyl-pyrimidine and -purine nucleosides (1995) (22)
Synthesis of 2',3'-dideoxy-3'-fluoro-L-ribonucleosides as potential antiviral agents from D-sorbitol. (2000) (21)
Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. (1999) (21)
Synthesis and potent anti-HIV activity of L-3'-fluoro-2',3'-unsaturated cytidine. (2001) (21)
From d-to l-nucleoside analogs as antiviral agents (1999) (21)
Analysis of Multiply Spliced Transcripts in Lymphoid Tissue Reservoirs of Rhesus Macaques Infected with RT-SHIV during HAART (2014) (21)
N-O diheterocyclic nucleosides: Synthesis of 2′-n-methyl-3′-hydroxymethyl-1′,2′-isoxazolidinylthymidine (1995) (21)
Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3′-Azido-2′,3′-Dideoxypurine Nucleosides (2009) (21)
Antiviral activity of 5-ethyl-2'-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs (1985) (20)
New Unnatural L-Nucleoside Enantiomers:From Their Stereospecific Synthesis to Their Biological Activities (1997) (20)
Synthesis and potent anti-HIV activity of L-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thiocytidine. (2002) (20)
Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rats (1991) (20)
Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages. (2016) (20)
Effect of stereoisomerism on the cellular pharmacology of beta-enantiomers of cytidine analogs in Hep-G2 cells. (1997) (20)
Asymmetric synthesis and anti-HIV activity of L-carbocyclic 2',3'-didehydro-2',3'-dideoxyadenosine. (1998) (20)
Nucleosides. 139. Synthesis and anticytomegalovirus and antiherpes simplex virus activity of 5'-modified analogues of 2'-fluoroarabinosylpyrimidine nucleosides. (1987) (20)
Synthesis and anti-HIV activity of conformationally restricted bicyclic hexahydroisobenzofuran nucleoside analogs. (2009) (20)
Lymphatic Targeting of anti-HIV Nucleosides: Distribution of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZdU) after Administration of Dipalmitoylphosphatidyl Prodrugs to Mice (1995) (20)
Enantioselective synthesis and antiviral activity of purine and pyrimidine cyclopentenyl C-nucleosides (2006) (20)
Sexual transmission risk perceptions and behavioural correlates of HIV concentrations in semen (2002) (19)
Synthesis of N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one, a novel compound with anti-hepatitis C virus activity. (2004) (19)
Molecular Mechanism of DAPD/DXG against Zidovudine- and Lamivudine- Drug Resistant Mutants: A Molecular Modelling Approach (2002) (19)
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. (2021) (19)
Synthesis and anti-human immunodeficiency virus (HIV-1) activity of 3'-deoxy-3'-(triazol-1-yl)thymidines and 2',3'-dideoxy-3'-(triazol-1-yl)uridines and inhibition of reverse transcriptase by their 5'-triphosphates. (1990) (19)
D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance. (2007) (19)
Synthesis and anti-HIV activity of l-2′-fluoro-2′,3′-unsaturated purine nucleosides (1998) (19)
Design of RNA Interactive Anti-HIV-1 Agents: Unfused Aromatic Intercalators. (2010) (19)
Pharmacokinetics of the Antiviral Agent β-d-2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine in Rhesus Monkeys (1999) (19)
Single-Amplicon Multiplex Real-Time Reverse Transcription-PCR with Tiled Probes To Detect SARS-CoV-2 spike Mutations Associated with Variants of Concern (2021) (19)
Characterization of dengue virus 2 growth in megakaryocyte-erythrocyte progenitor cells. (2016) (19)
Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5'-triphosphates. (2011) (19)
Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy (1993) (19)
Synthesis and evaluation of 2'-substituted cyclobutyl nucleosides and nucleotides as potential anti-HIV agents. (2007) (18)
Interplay of ancestral non-primate lentiviruses with the virus-restricting SAMHD1 proteins of their hosts (2018) (18)
Antiviral Activities of 2′-Fluorinated Arabinosyl—Pyrimidine Nucleosides (1988) (18)
Synthesis of novel spiro[2.3]hexane carbocyclic nucleosides via enzymatic resolution. (2004) (18)
Synthesis and structure-activity relationships of novel anti-hepatitis C agents: N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one derivatives. (2005) (18)
In situ Complexation Directs the Stereochemistry of N‐Glycosylation in the Synthesis of Oxathiolanyl and Dioxolanyl Nucleoside Analogues. (1992) (18)
Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals (2019) (18)
Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy (2005) (18)
Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of D- and L-D4FC-TP. (2004) (17)
New classes of fluorinated L-nucleosides; synthesis and antiviral activity. (1999) (17)
Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses (2019) (17)
Inhibition of Hepatitis B Virus Replication by Nucleoside Enantiomers of β-2′,3′-Dideoxypurine Analogues (1996) (17)
An improved synthesis of 6H-pyrido[4,3-b]carbazole derivatives (1975) (17)
Cellular Pharmacology of D-d4FC, a Nucleoside Analogue Active against Drug-Resistant HIV (2003) (17)
Ribonucleotide incorporation in yeast genomic DNA shows preference for cytosine and guanosine preceded by deoxyadenosine (2020) (17)
Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. (2002) (17)
Pharmacodynamics of (−)-β-2′,3′-Dideoxy-3′-Thiacytidine in Chronically Virus-Infected Woodchucks Compared to Its Pharmacodynamics in Humans (1998) (17)
Absolute Configuration of the Antiviral Agent (−)-cis-5-Fluoro-1-[2-Hydroxymethyl)-1,3-Oxathiolan-5-yl]Cytosine (1993) (16)
Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells (1993) (16)
Synthesis and biological properties of 5-o-carboranyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil. (1994) (16)
Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor (2006) (16)
Boron containing oligonucleotides. (1998) (16)
Carboranyl oligonucleotides. 3. Biochemical properties of oligonucleotides containing 5-(o-carboranyl-1-yl)-2'-deoxyuridine. (1996) (16)
In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of β-2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine (2005) (16)
Lethal mutagenesis as an antiviral strategy. (2022) (16)
Antiretroviral Activity, Biochemistry, and Pharmacokinetics of 3′‐Azido‐2′,3′‐Dideoxy‐5‐Methylcytidine a (1990) (15)
Lymphatic targeting of anti-HIV nucleosides: distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice. (1997) (15)
Tissue Disposition of 5‐o‐Carboranyluracil—A Novel Agent for the Boron Neutron Capture Therapy of Prostate Cancer (2004) (15)
Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. (2010) (15)
Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model (2008) (15)
Retinazone Inhibits Certain Blood-Borne Human Viruses Including Ebola Virus Zaire (2014) (15)
Synthesis of β-Enantiomers of N4-Hydroxy-3′-Deoxy-Pyrimidine Nucleosides and Their Evaluation against Bovine Viral Diarrhoea Virus and Hepatitis C Virus in Cell Culture (2004) (15)
Synthesis and Evaluation of 2,6-Modified Purine 2'-C-Methyl Ribonucleosides as Inhibitors of HCV Replication. (2016) (15)
Balancing Antiviral Potency and Host Toxicity: Identifying a Nucleotide Inhibitor with an Optimal Kinetic Phenotype for HIV-1 Reverse Transcriptase (2012) (15)
Cellular Pharmacology of the D- and L-Enantiomers of β-5-o-Carboranyl-2′-deoxyuridine (2000) (15)
Sulfated Alkyl Oligosaccharides Inhibit Human Immunodeficiency virus in vitro and Provide Sustained Drug Levels in Mammals (1995) (15)
Comparative Pharmacokinetics of Racivir®, (±)-β-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine in Rats, Rabbits, Dogs, Monkeys and HIV-Infected Humans (2005) (15)
Pharmacokinetics of 5-carboranyl-2'-deoxyuridine in rats. (1994) (15)
Template-assisted synthesis of adenine-mutagenized cDNA by a retroelement protein complex (2018) (15)
Safety, Pharmacokinetics, and Efficacy of (+/−)-β-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients (2005) (15)
Synthesis and anti-HIV-1 screening of novel N′-(1-(aryl)ethylidene)-2-(5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-4(1H)-yl)acetohydrazides (2014) (15)
Enantioselective synthesis and biological evaluation of 5-o-carboranyl pyrimidine nucleosides. (1999) (14)
ESR as a valuable tool for the investigation of the dynamics of EPC and EPC/cholesterol liposomes containing a carboranyl-nucleoside intended for BNCT. (2005) (14)
Practical considerations for developing nucleoside reverse transcriptase inhibitors. (2012) (14)
Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells. (2014) (14)
Efficient synthesis of exo-N-carbamoyl nucleosides: application to the synthesis of phosphoramidate prodrugs. (2012) (14)
Synthesis and evaluation of novel potent HCV NS5A inhibitors. (2012) (14)
Exploiting the Anti-HIV-1 Activity of Acyclovir: Suppression of Primary and Drug-Resistant HIV Isolates and Potentiation of the Activity by Ribavirin (2012) (14)
Synthesis of novel 3'-C-methyl-apionucleosides: an asymmetric construction of a quaternary carbon by Claisen rearrangement. (2000) (14)
Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine (2019) (14)
Synthesis and anti-HIV activity of l-β-3′-C-cyano-2′,3′-unsaturated nucleosides and l-3′-C-cyano-3′-deoxyribonucleosides (2003) (14)
Synthesis of [3.3.0] bicyclic isoxazolidinyl nucleosides (1996) (14)
Mechanism of Antiviral Activities of 3′-Substituted L-Nucleosides against 3Tc-Resistant HBV Polymerase: A Molecular Modelling Approach (2003) (14)
Synthesis of 3'-fluoro-2',3'-dideoxy-2',3'-didehydro-4'-ethynyl-D- and -L-furanosyl nucleosides. (2004) (14)
Molecular docking and antiviral activity of N-substituted benzyl/phenyl-2-(3,4-dimethyl-5,5-dioxidopyrazolo[4,3-c][1,2]benzothiazin-2(4H)-yl)acetamides. (2015) (14)
Viral Decay Kinetics in the Highly Active Antiretroviral Therapy-Treated Rhesus Macaque Model of AIDS (2010) (14)
Synthesis of novel pyrazolobenzothiazine 5,5-dioxide derivatives as potent anti-HIV-1 agents (2014) (14)
Potent Antiviral Effect of Reverset™ in HIV-1-Infected Adults following a Single Oral Dose (2003) (14)
Substrate specificity of Escherichia coli thymidine phosphorylase for pyrimidine nucleosides with anti-human immunodeficiency virus activity. (1992) (14)
Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside (2021) (14)
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. (2011) (13)
Chemoenzymatic syntheses and anti-HIV-1 activity of glucose-nucleoside conjugates as prodrugs. (2010) (13)
Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial. (2015) (13)
Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients (2015) (13)
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors. (2013) (13)
Synthesis of 5′,9-anhydro-3-(β-d-ribofuranosyl)xanthine, and 3,5′-anhydro-xanthosine as potential anti-hepatitis C virus agents (2005) (13)
Boron neutron capture therapy of cancers: nucleic bases, nucleosides, and oligonucleotides as potential boron carriers (1995) (13)
Synthesis of purine modified 2'-C-methyl nucleosides as potential anti-HCV agents. (2011) (13)
Mobile Health Intervention to Reduce HIV Transmission: A Randomized Trial of Behaviorally Enhanced HIV Treatment as Prevention (B-TasP) (2018) (13)
Synthesis, molecular docking and antiviral screening of novel N′-substitutedbenzylidene-2-(4-methyl-5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-1(4H)-yl)acetohydrazides (2014) (13)
Biochemical Studies on the Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to 1-(β-d-Dioxolane)Thymine Triphosphate (2007) (13)
Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V. (2009) (13)
Synthesis of novel isoxazolinyl substituted imidazo[1,2-a]pyridine C-nucleoside analogs (1998) (13)
Treatment of isografted 9L rat brain tumors with beta-5-o-carboranyl-2'-deoxyuridine neutron capture therapy. (2000) (13)
Engineering of a Chimeric RB69 DNA Polymerase Sensitive to Drugs Targeting the Cytomegalovirus Enzyme* (2009) (13)
Effect of β-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells (1996) (13)
Approaches for the development of antiviral compounds: the case of hepatitis C virus. (2009) (13)
Relationship of the Molecular Size and Charge Density of Polyoxometalates to Their anti-gp120-CD4-binding Activity (1994) (13)
Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1 (1992) (12)
Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals (2010) (12)
Synthesis of 5'-methylene-phosphonate furanonucleoside prodrugs: application to D-2'-deoxy-2'-α-fluoro-2'-β-C-methyl nucleosides. (2012) (12)
Anti-human immunodeficiency virus type-1 (HIV-1) and anti-hepatitis B virus (HBV) activities of (2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)nucleosides (1995) (12)
Pharmacokinetics of the Antiviral Agent β-d-2′-Deoxy-2′-Fluoro-2′-C-Methylcytidine in Rhesus Monkeys (2007) (12)
Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs. (2017) (12)
Cellular metabolism of 3'-azido-2',3'-dideoxyuridine with formation of 5'-O-diphosphohexose derivatives by previously unrecognized metabolic pathways for 2'-deoxyuridine analogs. (1990) (12)
Virus-induced thymidine kinases as markers for typing herpes simplex viruses and for drug sensitivity assays. (1982) (12)
Potent Anti‐HIV and Anti‐HBV Activities of (‐)‐L‐β‐Dioxolane‐C and (+)‐L‐β‐Dioxolane‐T and Their Asymmetric Syntheses. (1993) (12)
Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors. (2016) (12)
Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. (2001) (12)
Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. (2017) (12)
Synthesis and Anti-HIV Evaluation of 3′-Triazolo Nucleosides (2011) (11)
Synthesis of 2‐Deoxy‐2‐Fluoro‐2‐C‐Methyl‐D‐Ribofuranoses (2006) (11)
A New Point Mutation (P157S) in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Confers Low-Level Resistance to (−)-β-2′,3′-Dideoxy-3′-Thiacytidine (1999) (11)
Synthesis of oxathiolane imidazole nucleosides. (2002) (11)
Pharmacokinetics of 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats. (1994) (11)
Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir (1997) (11)
Cross-sectional IgM and IgG profiles in SARS-CoV-2 infection (2020) (11)
Physicochemical Properties, Bioconversion and Disposition of Lipophilic Prodrugs of 2′,3′-Dideoxycytidine (1996) (11)
Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes. (2001) (11)
Development of a Novel Mouse Model to Evaluate Drug Candidates against Hepatitis B Virus (2007) (11)
Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors (2013) (11)
Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy (2001) (11)
A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin (2016) (11)
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. (2019) (11)
Synthesis and anti-HIV activity of (−)-β- d-(2 R,4 R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (−)-β- d-(2 R,4 R)-1,3-dioxolane guanosine (DXG) prodrugs (2007) (11)
Synthesis of 5-haloethynyl- and 5-(1,2-dihalo)vinyluracil nucleosides: antiviral activity and cellular toxicity. (2005) (11)
Development of a Population Simulation Model for HIV Monotherapy Virological Outcomes Using Lamivudine (2007) (11)
5-phenylthioacyclouridine: a potent and specific inhibitor of uridine phosphorylase. (2000) (11)
A CRISPR/Cas9 approach reveals that the polymerase activity of DNA polymerase β is dispensable for HIV-1 infection in dividing and nondividing cells (2017) (11)
Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094 (2016) (11)
Synthesis and biological activities of some uronic acids, uronates, uronamides, and urononitriles of pyrimidine nucleosides. (1978) (11)
Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus (2019) (10)
Synthesis and biological properties of the four optical isomers of 5-o-carboranyl-2',3'-didehydro-2',3'-dideoxyuridine. (1998) (10)
Enhanced Antiretroviral Therapy in Rhesus Macaques Improves RT-SHIV Viral Decay Kinetics (2014) (10)
Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses. (2013) (10)
GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition (2020) (10)
Synthesis and Antiviral Evaluation of 2′,3′-Dideoxy-2′-fluoro-3′-C-hydroxymethyl-β-D-arabinofuranosyl Pyrimidine Nucleosides (2003) (10)
A Short Synthesis of 2′,3′-Didehydro-3′-deoxythymidine (1993) (10)
Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study (2021) (10)
Carboranyl Oligonucleotides for Antisense Technology and Boron Neutron Capture Therapy of Cancers (1994) (10)
Antiviral Activity and Pharmacokinetics of 1-(2,3-Dideoxy-2-Fluoro-β-l-Glyceropent-2-Enofuranosyl)Cytosine (2003) (10)
1,3‐Dioxolanylpurine Nucleosides (2R,4R), e.g. (II), and (2R,4S) with Selective Anti‐HIV‐1 Activity in Human Lymphocytes. (1994) (10)
Antiviral and Cellular Metabolism Interactions between Dexelvucitabine and Lamivudine (2007) (10)
Synthesis and Biological Activity of 5′,9-Anhydro-3-Purine-ISONucleosides as Potential Anti-Hepatitis C Virus Agents (2007) (10)
Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs. (2017) (10)
Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator (2021) (10)
Cellular Pharmacology of 9-(β-D-1,3-dioxolan-4-yl) Guanine and its Lack of Drug Interactions with Zidovudine in Primary Human Lymphocytes (2007) (10)
Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy (2000) (10)
PAMAM Dendrimers and Branched Polyethyleneglycol (Nanoparticles) Prodrugs of (-)-β-D-(2R, 4R)-dioxolane-thymine (DOT) and Their Anti-HIV Activity (2006) (10)
Anti‐HIV‐1, Cytotoxic, and Biological Properties of Selected Polyoxometalate Compounds a (1990) (10)
Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase (2017) (10)
Synthesis and Anti-HIV Activity of β-D-3′-Azido-2′,3′-unsaturated Nucleosides and β-D-3′-Azido-3′-deoxyribofuranosylnucleosides (2005) (10)
In Vitro Evaluation of Anticryptosporidial Agents Using MDCK Cell Culture and Chemiluminescence Immunoassay (1996) (9)
Hydrocephalus induction in mice infected with herpes simplex virus type 2 after antiviral treatment. (1995) (9)
Intracellular Metabolism of β-l-2′,3′-Dideoxyadenosine: Relevance to Its Limited Antiviral Activity (2000) (9)
Residual Viremia in an RT-SHIV Rhesus Macaque HAART Model Marked by the Presence of a Predominant Plasma Clone and a Lack of Viral Evolution (2014) (9)
HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability (2018) (9)
5'-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies. (2009) (9)
Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection. (2019) (9)
Sofosbuvir (Sovaldi): The First‐in‐Class HCV NS5B Nucleotide Polymerase Inhibitor (2015) (9)
Inhibition of B Virus (Macacine herpesvirus 1) by Conventional and Experimental Antiviral Compounds (2009) (9)
Anti-HIV activity of new pyrazolobenzothiazine 5,5-dioxide-based acetohydrazides (2015) (9)
Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activity of pyrimidine oxathiolane nucleosides (1993) (9)
Antiviral Effect of Orally Administered (−)-β-d-2-Aminopurine Dioxolane in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection (2007) (9)
A General Synthetic Method of 5-Carboranyluracil Nucleosides with Potential Antiviral Activity and use in Neutron Capture Therapy (1997) (9)
Sonication-Assisted Synthesis of (E)-2-Methyl-but-2-enyl Nucleoside Phosphonate Prodrugs (2016) (9)
Synthesis and anti-HIV activity of 5-haloethynyl and 5-(1,2-dihalo)vinyl analogues of AZT and FLT. (2008) (9)
Universal Profiling of HIV-1 Pol for Genotypic Study and Resistance Analysis Across Subtypes (2011) (9)
The RADx Tech Test Verification Core and the ACME POCT in the Evaluation of COVID-19 Testing Devices: A Model for Progress and Change (2021) (9)
Randomized, Double-Blind, Multicenter Safety and Efficacy Study of Rifalazil Compared with Azithromycin for Treatment of Uncomplicated Genital Chlamydia trachomatis Infection in Women (2014) (9)
Structural and Antiviral Studies of the Human Norovirus GII.4 Protease. (2019) (9)
Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern (2022) (9)
SAMHD 1 controls cell cycle status , apoptosis and HIV-1 infection in monocytic THP-1 cells (8)
Biotransformation and pharmacokinetics of prodrug 9-(β-d-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(β-d-1,3-dioxolan-4-yl)guanine in mice (1997) (8)
In vitro and in vivo evaluation of 6-azido-2',3'-dideoxy-2'-fluoro-beta-D-arabinofuranosylpurine and N6-methyl-2',3'-dideoxy-2'-fluoro-beta-D-arabinofuranosyladenine as prodrugs of the anti-HIV nucleosides 2'-F-ara-ddA and 2'-F-ara-ddI. (1996) (8)
Conformational Analysis of 2′,3′‐Didehydro‐2′,3′‐dideoxypyrimidine Nucleosides (1993) (8)
Retrovirus Reverse Transcriptases Containing a Modified YXDD Motif (2005) (8)
Catabolic disposition of 3'-azido-2',3'-dideoxyuridine in hepatocytes with evidence of azido reduction being a general catabolic pathway of 3'-azido-2',3'-dideoxynucleosides. (1992) (8)
Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques (2020) (8)
Pharmacokinetics of (2)-29-39-Dideoxy-39-Thiacytidine in Woodchucks (1996) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
Host SAMHD1 protein restricts endogenous reverse transcription of HIV-1 in nondividing macrophages (2018) (8)
Evaluation of Single and Combination Therapies with Tenofovir Disoproxil Fumarate and Emtricitabine In Vitro and in a Robust Mouse Model Supporting High Levels of Hepatitis B Virus Replication (2012) (8)
Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors. (2013) (8)
Pharmacology and Pharmacokinetics of the Antiviral Agent β-d-2′,3′-Dideoxy-3′-Oxa-5-Fluorocytidine in Cells and Rhesus Monkeys (2005) (8)
Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors. (2018) (8)
SYNTHESIS AND IN VITRO ANTI-HCV ACTIVITY OF β-D- and L-2′-DEOXY-2′-FLUORORIBONUCLEOSIDES (2005) (8)
Chemistry of 6H-pyrido[4,3-b]carbazoles. Part V. A simple synthe of ellipticines (1976) (8)
Synthesis of enantiomerically pure D-FDOC, an anti-HIV agent. (2004) (8)
HIV‐1 Neutralization and Tumor Cell Proliferation Inhibition in vitro by Simplified Analogues of Pyrido(4,3,2‐mn)thiazolo(5,4‐b)acridine Marine Alkaloids. (1992) (8)
Pharmacokinetics of the Antiviral Agent β-l-3′-Fluoro-2′,3′-Didehydro-2′,3′-Dideoxycytidine in Rhesus Monkeys (2005) (8)
Stereoselective synthesis, chemistry and antiviral evaluation of 1-(2,3-dideoxy-3-C-hydroxymethyl-beta-D-threo-pentofuranosyl)thymine derivatives. (1995) (8)
Synthesis of Six-Membered Nucleoside Analogs. Part 1: Pyrimidine Nucleosides Based on the 1,3-Dioxane Ring System (1997) (7)
7-Deaza-7-Fluoro-2'-C-Methyladenosine Inhibits Zika virus Infection and Viral-induced Neuroinflammation. (2020) (7)
Effect of Dehydroepiandrosterone in Lymphocytes and Macrophages Infected with Human Immunodeficiency Viruses (1990) (7)
Derivatives of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-phenyluracil and 5-benzyluracil. Synthesis and biological properties (1994) (7)
Selection and Characterization of HIV-1 with a Novel S68 Deletion in Reverse Transcriptase (2011) (7)
Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy (2000) (7)
Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus (2019) (7)
Anti-HBV specific beta-L-2'-deoxynucleosides. (2001) (7)
Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases. (2009) (7)
Effect of AZT, AzddU, FDT, and BCH-189 nucleotides on DNA chain termination mediated by HIV-1 reverse transcriptase (1991) (7)
Pharmacokinetics of the Anti-Human Immunodeficiency Virus Agent 1-(β-d-Dioxolane)Thymine in Rhesus Monkeys (2007) (7)
High-performance liquid chromatographic determination of (-)-β-D-2-aminopurine dioxolane and (-)-β-D-2-amino-6-chloropurine dioxolane, and their metabolite (-)-β-D-dioxolane guanine in monkey serum, urine and cerebrospinal fluid (1997) (7)
Brain Targeting of Anti‐HIV Nucleosides (1990) (7)
SYNTHESIS OF N3,5′-CYCLO-4-(β-D-RIBOFURANOSYL)-VIC-TRIAZOLO[4,5-b]PYRIDIN-5-ONE AND ITS 3′-DEOXYSUGAR ANALOGUE AS POTENTIAL ANTI-HEPATITIS C VIRUS AGENTS (2005) (7)
Anti-HIV-1 screening of (2E)-3-(2-chloro-6-methyl/methoxyquinolin-3-yl)-1-(aryl)prop-2-en-1-ones (2013) (7)
Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs. (2019) (7)
Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase. (2012) (7)
Synthesis and Antiviral Activities of Enantiomeric 1-[2-(Hydroxymethyl) Cyclopropyl] Methyl Nucleosides (2000) (7)
The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency (2021) (7)
Correlation of SARS-CoV-2 Subgenomic RNA with Antigen Detection in Nasal Midturbinate Swab Specimens (2021) (7)
Synthesis and Biological Evaluation of 4'-C,3'-O-Propylene-Linked Bicyclic Nucleosides. (2011) (7)
Drug combinations for treatment of mice infected with acyclovir-resistant herpes simplex virus (1987) (7)
Synthesis of 6-imino-5-tetrahydro-1H-2-pyrrolylidenhexahydro-2,4-pyrimidinediones as intermediates for the synthesis of C-azanucleosides (2010) (7)
Enantiomeric Synthesis of (+)‐BCH‐189 ((+)‐(2S,5R)‐1‐(2‐(Hydroxymethyl) ‐1,3‐oxathiolan‐5‐yl)cytosine) (I) from D‐Mannose and Its Anti‐HIV Activity. (1992) (6)
Anti-human immunodeficiency activity of novel 2-arylpyrrolidine analogs (2017) (6)
Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice (2017) (6)
SYNTHESIS AND ANTI-HEPATITIS C VIRUS ACTIVITY OF NUCLEOSIDE DERIVATIVES OF N 3,5′-ANHYDRO-4-(β-D-RIBOFURANOSYL)-8-AZAPURIN-2-ONES (2005) (6)
2('),3(')-didehydro-2('),3(')-dideoxynucleosides are degraded to furfuryl alcohol under acidic conditions. (2004) (6)
Solid-State Conformation of Anti-Human Immunodeficiency Virus Type-1 Agents: Crystal Structures of Three 3′-Azido-3′-deoxythymidine Analogues (1988) (6)
Synthesis of 2-fluoro-substituted and 2,6-modified purine 2',3'-dideoxy-2',3'-difluoro-d-arabinofuranosyl nucleosides from d-xylose. (2019) (6)
Pharmacokinetics of 3′-azido-2′,3′-dideoxy-5-methylcytidine in Rats (1990) (6)
The Boron–Neutron Capture Agent β-d-5-o-Carboranyl-2′-deoxyuridine Accumulates Preferentially in Dividing Brain Tumor Cells (2005) (6)
Selective protection of toxicity of 2',3'-dideoxypyrimidine nucleoside analogs by beta-D-uridine in human granulocyte-macrophage progenitor cells. (1996) (6)
Synthesis and Antiviral Activity of Various 3′-Azido Analogues of Pyrimidine Deoxyribonucleosides Against Human Immunodeficiency Virus (HIV-1, HTLV-III/LAV). (1988) (6)
Scaleable processes for the synthesis of (-)-β-D-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (-)-β-D-2-aminopurine dioxolane (APD). (2012) (6)
Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases. (2015) (6)
Synthesis and Antiviral Activity of Purine 2′,3′-Dideoxy-2′,3′-Difluoro-D-Arabinofuranosyl Nucleosides (2009) (6)
Erratum to “Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses” [Antiviral Res. 71 (2006) 322–334] (2006) (6)
Anti-Human Immunodeficiency Virus, Toxicity in Cell Culture, and Tolerance in Mammals of a Water-Soluble Fullerene (1994) (6)
Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells. (2015) (6)
Review Hepatitis B Virus Resistance to Lamivudine and its Clinical Implications (2002) (6)
Comparison of Physicochemical and Biological Properties of (o-Carboran-1-YL)methylphosphonate and Methylphosphonate Oligonucleotides (1997) (6)
Metabolism of Nucleosides and Nucleotides Prodrugs. (2017) (6)
Lack of Pharmacokinetic Interaction between Amdoxovir and Reduced- and Standard-Dose Zidovudine in HIV-1-Infected Individuals (2009) (6)
Enzyme-Mediated Enantioselective Preparation of Pure Enantiomers of the Antiviral Agent 2′,3′-Dideoxy-5-fluoro-3′-thiacytidine (FTC) (I) and Related Compounds. (1993) (6)
Novel and potent HBV capsid modulator reduces HBeAg and cccDNA in core site directed T109I mutant in HepNTCP cells (2018) (6)
Synthesis of (2S)-2-Chloro-2-fluororibolactone via Stereoselective Electrophilic Fluorination. (2017) (6)
Antiviral Agents Derived from Novel 1-adamantyl Singlet Nitrenes (2012) (6)
Anti-influenzavirus-activities of polyoxometalates (1995) (5)
Synthesis of 6‐Imino‐5‐tetrahydro‐1H‐2‐pyrrolylidenhexahydro‐2,4‐pyrimidinediones as Intermediates for the Synthesis of C‐Azanucleosides. (2010) (5)
Role of nucleosides in virus and cancer chemotherapy. (1979) (5)
Correlation of Human Immunodeﬁciency Virus Type 1 RNA Levels in Blood and the Female Genital Tract (1999) (5)
Synthesis of cyclopentanyl carbocyclic 5-fluorocytosine ((-)-5-fluorocarbodine) using a facially selective hydrogenation approach. (2013) (5)
Antiviral Drug Resistance: From the Laboratory to the Patient (1998) (5)
Synthesis of 2',3'-dideoxy-2'-fluoro-L-threo-pentofuranosyl nucleosides as potential antiviral agents. (1999) (5)
Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides. (1997) (5)
Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors (2015) (5)
Erratum for Amblard et al., “Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice” (2020) (5)
Efficient pre-catalytic conformational change of reverse transcriptases from SAMHD1 non-counteracting primate lentiviruses during dNTP incorporation. (2019) (5)
Elimination of Aicardi–Goutières syndrome protein SAMHD1 activates cellular innate immunity and suppresses SARS-CoV-2 replication (2022) (5)
Progress in the Development Of Natural Products for Human Immunodeficiency Viruses Infections (1992) (5)
Crystal structure and anti herpes simplex virus activity of 2,2'-anhydro-1-beta-D-arabinofuranosylthymine. (1982) (5)
Synthesis and antiviral evaluation of 2′,3′-dideoxy-2′,3′-difluoro-D-arabinofuranosyl 2,6-disubstituted purine nucleosides (2015) (5)
In Vitro Expression of mRNA Coding For a Cryptosporidium parvum Oocyst Wall Protein (1996) (5)
Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus. (2020) (5)
A simple synthesis of ellipticine and 11-demethylellipticine (1975) (5)
Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. (2020) (5)
Synthesis and Structure-Activity Relationships of 6-Substituted 2′,3′-Dideoxypurine Nucleosides as Potential Anti-Human Immunodeficiency Virus Agents. (1990) (5)
HIV nucleoside reverse transcriptase inhibitors. (2022) (5)
The Crystal and Molecular Structure of 3′-Fluoro-3′-Deoxythymidine, a Potent Anti-HIV-1 Nucleoside (1990) (5)
Interaction of 2′-deoxyguanosine Triphosphate Analogue Inhibitors of HIV Reverse Transcriptase with Human Mitochondrial DNA Polymerase γ (2007) (5)
In silico study supports the efficacy of a reduced dose regimen for stavudine. (2011) (5)
Covid‐19 will not “magically disappear”: Why access to widespread testing is paramount (2020) (5)
Asymmetric Synthesis of Cyclopropyl Carbocyclic Nucleosides (1995) (5)
Brain Targeting of anti-HIV Nucleosides: Ether Prodrugs of 3′-Azido-2′,3′-Dideoxyuridine (AZdU) and 3′-Azido-3′-Deoxythymidine (AZT) (1993) (5)
Pharmacokinetics of β-l-2′,3′-Dideoxy-5-Fluorocytidine in Rhesus Monkeys (1997) (5)
Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery (2020) (5)
Nb-containing polyoxometalate HIV-1 protease inhibitors (1997) (5)
Dynamic SIMS ion microscopy imaging of intracellular boron accumulation from carboranyl nucleosides in glioma cells. (2001) (5)
Contemporary Approaches to the Discovery and Development of Broad-Spectrum Natural Product Prototypes for the Control of Coronaviruses (2021) (4)
Antiviral Activities of β-Enantiomers of 3′-Substituted-3′-deoxythymidine Analogs (1997) (4)
Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine. (2014) (4)
Isolation and partial characterization of Cryptosporidium sporozoite and oocyst wall recombinant proteins. (1994) (4)
Unexpected formation of novel butenolides by thermolysis of o-carboranyl substituted cyclobutenones (1998) (4)
Mechanism of Anti-Human Immunodeficiency Virus Activity of β-d-6-Cyclopropylamino-2′,3′-Didehydro-2′,3′-Dideoxyguanosine (2005) (4)
Synthesis of 4′-Substituted-2′-Deoxy-2′-α-Fluoro Nucleoside Analogs as Potential Antiviral Agents (2020) (4)
Polyoxometalates and Fullerenes as Anti-HIV Agents (1999) (4)
Acute acalculous cholecystitis during zika virus infection in an immunocompromised patient (2018) (4)
Effect of genetically determined host factors on the efficacy of vidarabine, acyclovir and 5-trifluorothymidine in herpes simplex virus type 1 infection. (1994) (4)
GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition (2022) (4)
Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs. (2014) (4)
The Base Component of 3′-Azido-2′,3′-Dideoxynucleosides Influences Resistance Mutations Selected in HIV-1 Reverse Transcriptase (2011) (4)
Simultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assay. (2009) (4)
Molecular and serum epidemiology of HBV and HCV infection and the impact of antiviral agents in China (2003) (4)
Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy (2001) (4)
TREM2+ and interstitial macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques (2021) (4)
Effect of induced dNTP pool imbalance on HIV-1 reverse transcription in macrophages (2019) (4)
The synthesis and biological evaluation of novel bridging nucleoside analogues. (2002) (4)
Dipyridamole Potentiates the Activity of Zidovudine and Other Dideoxynucleosides against HIV‐1 in Cultured Cells a (1990) (4)
Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes (2022) (4)
The discovery of Zika virus NS2B-NS3 inhibitors with antiviral activity via an integrated virtual screening approach. (2022) (4)
Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes (1997) (4)
In Vitro Testing of Therapeutics against SIV and HIV (1990) (4)
Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys. (1993) (4)
Characterization of Hepatitis B Virus Inhibition by Novel 2′-Fluoro-2′,3′-Unsaturated Beta-D- and l-nucleosides (2005) (4)
Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. (2012) (4)
High-performance liquid chromatographic determination of (-)-beta-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, using ultraviolet and on-line radiochemical detection. (1995) (4)
Synthesis and Biological Evaluation of New Enantiomers of 5-O-Carboranyl Pyrimidine Nucleosides (1999) (4)
In Vitro and In Vivo Metabolism and Pharmacokinetics of bis [(T-Butyl)-S-acyl-2-thioethyl]-β-L-2′,3′-dideoxy-5-fluorocytidine Monophosphate (2000) (4)
Efficient Pd(0)‐Catalyzed Synthesis of 1,2,3‐Triazolo‐3′‐deoxycarbanucleosides and Their Analogues. (2006) (3)
The Cellular Metabolism of AzdU (1990) (3)
Synthesis and Antiviral Evaluation of (1,4-Disubstituted-1,2,3-Triazol)-(E)-2-Methyl-but-2-Enyl Nucleoside Phosphonate Prodrugs (2021) (3)
Telbivudine Exerts no Antiviral Activity against HIV-1 In Vitro and in Humans (2011) (3)
Synthesis and anti‐HIV Activity of L‐β‐3′‐C‐Cyano‐2′,3′‐unsaturated Nucleosides and L‐3′‐C‐Cyano‐3′‐deoxyribonucleosides. (2003) (3)
Cloning and Expression of Sporozoite and Oocyst Cryptosporidium parvum Recombinant Proteins. (1996) (3)
Reply to Troth et al (2021) (3)
Pre-steady state kinetic analysis of HIV-1 reverse transcriptase for non-canonical ribonucleoside triphosphate incorporation and DNA synthesis from ribonucleoside-containing DNA template. (2015) (3)
The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates. (2022) (3)
Antiviral drugs: modes of action and strategies for therapy. (1981) (3)
Structural and functional characterization explains loss of dNTPase activity of the cancer-specific R366C/H mutant SAMHD1 proteins (2021) (3)
Ethyl 1-benzoyl-4-chloro-2-phenylprolinate (2007) (3)
Potential controlled anodic oxidation of 4-(3,4-dimethoxybenzyl)-6,7-dimethoxyisochroman-3-one (1972) (3)
Asymmetric Synthesis and Biological Evaluation of β-L-(2R,5S)- and α-L-(2R,5R)-1,3-Oxathiolane-Pyrimidine and -Purine Nucleosides as Potential Anti-HIV Agents. (1994) (3)
Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine (2003) (3)
Synthesis, Antiviral Activity, Cytotoxicity, and Cellular Pharmacology of 5-Carboranyl-Pyrimidine Nucleosides (1993) (3)
Intracellular metabolism of beta-L-ddAMP-bis(tbutylSATE), a potent inhibitor of hepatitis B virus replication. (1999) (3)
Long-term Virological and Adherence Outcomes to Antiviral Treatment in a 4-year Cohort Chronic HBV Study (2019) (3)
Stereoselective synthesis and antiviral activity of D-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides. (2002) (3)
Dose-Dependent Pharmacokinetics of 3′-azido-2′,3′-dideoxyuridine in Rats (1991) (3)
Disproportionate presence of adenosine in mitochondrial and chloroplast DNA of Chlamydomonas reinhardtii (2020) (3)
Pharmacokinetics of (—)-β-L-2′,3′-Dideoxy-3′-thiacytidine in Rats (1996) (3)
Intracellular metabolism and potential cardiotoxicity of a β-D-2’-C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication (2020) (3)
NUCLEOSIDES. 133. SYNTHESIS OF 5‐ALKENYL‐1‐(2‐DEOXY‐2‐FLUORO‐β‐D‐ARABINOFURANOSYL)CYTOSINES AND RELATED PYRIMIDINE NUCLEOSIDES AS POTENTIAL ANTIVIRAL AGENTS (1985) (3)
Viral protein X reduces the incorporation of mutagenic noncanonical rNTPs during lentivirus reverse transcription in macrophages (2019) (3)
FRI-157-Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation (2019) (3)
Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. (2007) (3)
N4-Acyl-Modified D-2′,3′-Dideoxy-5-Fluorocytidine Nucleoside Analogues with Improved Antiviral Activity (2003) (3)
Brain Targeting of anti-HIV Nucleosides: in vitro and in vivo Evaluation of 6-chloro-2′,3′-dideoxypurine, a Lipophilic Prodrug of 2′,3′-dideoxyinosine (1994) (3)
Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients. (2005) (3)
Disparate effects of Cytotoxic Chemotherapy on the Antiviral Activity of Antiretroviral Therapy: Implications for Treatments of HIV-Infected Cancer Patients (2019) (3)
Emtricitabine: A Viewpoint by Raymond F. Schinazi (2003) (3)
Pharmacokinetics and toxicity of the human immunodeficiency virus inhibitor 1-ethoxymethyl-6-phenylselenenyl-5-ethyluracil in rodents. (1995) (2)
Synthesis of 7-trifluoromethyl-7-deazapurine ribonucleoside analogs and their monophosphate prodrugs (2020) (2)
Enhanced enzyme kinetics of reverse transcriptase variants cloned from animals infected with SIVmac239 lacking viral protein X (2020) (2)
Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies (2022) (2)
Editorial overview: Antiviral strategies. (2016) (2)
Synthesis , evaluation of anti-HIV-1 and anti-HCV activity of novel 2 0 , 3 0-dideoxy-2 0 , 2 0-difluoro-4 0-azanucleosides (2012) (2)
Synthesis and Biological Properties of the Four Optical Isomers of 5‐o‐Carboranyl‐2′,3′‐didehydro‐2′,3′‐dideoxyuridine. (1998) (2)
Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10. (2000) (2)
Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3′-azido-2′,3′-dideoxyguanosine-5′-triphosphates as adenosine analogs (2011) (2)
Anti-infective pyrroloiminoquinone alkaloids from a deep-water Alaskan sponge of the genus Latrunculia (2008) (2)
Synthesis, structure-activity relationships, and drug resistance of beta-d-3'-fluoro-2',3'-unsaturated nucleosides as anti-HIV Agents. (2004) (2)
Synthesis and Anti-HIV Activity of L-2′-Fluoro-2′,3′-Unsaturated Purine Nucleosides. (1998) (2)
Anti‐Human Immunodeficiency and Anti‐Hepatitis B Virus Activities of . beta.‐L‐2′,3′‐Dideoxypurine Nucleosides. (1996) (2)
SAMHD1-Mediated Negative Regulation of Cellular dNTP Levels: HIV-1, Innate Immunity, and Cancers (2018) (2)
Corrigendum to “Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks” (2000) (2)
Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance (2020) (2)
2′-Fluoro-4′-thio-2′,3′-unsaturated Nucleosides: Anti-HIV Activity, Resistance Profile, and Molecular Modeling Studies (2003) (2)
ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B (2020) (2)
Synthesis and Antiviral Activity of Purine 2′,3′-Dideoxy-2′,3′-difluoro-D-arabinofuranosyl Nucleosides. (2010) (2)
Disentangling the lifespans of hepatitis C virus‐infected cells and intracellular vRNA replication‐complexes during direct‐acting anti‐viral therapy (2020) (2)
Derivatives of 1‐(2‐Deoxy‐2‐fluoro‐β‐D‐arabinofuranosyl)‐5‐ phenyluracil and ‐5‐benzyluracyl. Synthesis and Biological Properties. (1995) (2)
Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy. (2003) (2)
Treatment of Isografted 9 L Rat Brain Tumors with b-5o-Carboranyl-2 *-Deoxyuridine Neutron Capture Therapy 1 (2000) (2)
Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir. (1998) (2)
Correction for Mavigner et al., “Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques” (2019) (2)
Synthesis and Anti-Hcv Activity of N 9, 5′-Cyclo-3-(β-D-Ribofuranosyl)-8-Azapurin-2-One Derivatives (2005) (2)
RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests (2021) (2)
Comparative metabolism of the antiviral dimer AZT-P-ddl and the monomers zidovudine and didanosine by rat, monkey and human hepatocytes (1997) (2)
Synthesis and anti‐HIV Evaluation of 3′‐Triazolo Nucleosides. (2012) (2)
A Synthetic Route to 3-(Dialkylamino)phenothiazin-5-ium Salts and 3,7- Disubstituted Derivatives Containing Two Different Amino Groups. (1994) (2)
Synthesis and Biological Evaluation of 2′,3′-Didehydro-2′,3′-dideoxy-5- fluorocytidine (D4FC) Analogues: Discovery of Carbocyclic Nucleoside Triphosphates with Potent Inhibitory Activity against HIV-1 Reverse Transcriptase1 (1999) (2)
Carboranyl Oligonucleotides. Part 1. Synthesis of Thymidine(3′,5′) thymidine (o-Carboran-1-ylmethyl)phosphonate. (1994) (2)
Evaluation of therapies for hepatitis B virus in the HBV transgenic SCID mouse model (2003) (2)
Novel 1′-homo-N-2′-deoxy-α-nucleosides: synthesis, characterization and biological activity (2020) (2)
Synthesis of thymidine derivatives 3'-modified with a polar three-atom group as potential anti-HIV-1 agents (1992) (2)
Dihydroxyboryldeoxyuridine (DBDU); can a borated nucleoside deceive the DNA molecule (1985) (2)
Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors. (2015) (2)
Viral Pharmacodynamic Model for (–)-β-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine (Emtricitabine) in Chronically Infected Woodchucks (2002) (2)
Synthesis and anti-HIV activity of beta-D-3'-azido-2',3'-unsaturated nucleosides and beta-D-3'-azido-3'-deoxyribofuranosylnucleosides. (2005) (2)
ASYMMETRIC SYNTHESIS OF CARBOCYCLIC PYRIMIDINE NUCLEOSIDES VIA π-ALLYLPALLADIUM COMPLEX (2001) (2)
Biotransformation and pharmacokinetics of prodrug 9-(beta-D-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(beta-D-1,3-dioxolan-4-yl)guanine in mice. (1997) (2)
Expression, Purification and Characterization of a GII.4 Norovirus Protease from Minerva Virus. (2018) (1)
Erratum: Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ (Proceedings of the National Academy of Sciences of the United States of America (2015) 112 (8596-8601) DOI: 10.1073/pnas.1421733112) (2016) (1)
Biological Properties of Dodeca(Thymidine Phosphates) Containing 5-(O-Carboran-1-Yl)-2″-Deoxyuridine (1996) (1)
Synthesis and in vitro anti-HCV activity of beta-D- and 1-2'-deoxy-2'-fluororibonucleosides. (2005) (1)
Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study (2021) (1)
1210 GNS-227: A NEW POTENT AND SELECTIVE HCV NS3 PROTEASE INHIBITOR WITH A HIGH GENETIC BARRIER TO RESISTANCE (2011) (1)
Asymmetric Synthesis and anti-HIV Activity of L-Carbocyclic 2′,3′-Didehydro-2′,3′-dideoxyadenosine. (1998) (1)
Efficient Synthesis of Various Acycloalkenyl Derivatives of Pyrimidine Using Cross‐Metathesis and Pd(0) Methodologies. (2005) (1)
Tissue Disposition of 5‐o‐Carboranyluracil — A Novel Agent for the Boron Neutron Capture Therapy of Prostate Cancer. (2004) (1)
Erratum to: Synthesis and anti-HIV-1 screening of novel N′-(1-(aryl)ethylidene)-2-(5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-4(1H)-yl)acetohydrazides (2014) (1)
2′‐ and/or 3′‐Deoxy‐β‐L‐pentofuranosyl Nucleoside Derivatives: Stereospecific Synthesis and Antiviral Activities. (1995) (1)
Cognitively Based Compassion Training for HIV Immune Nonresponders—An Attention-Placebo Randomized Controlled Trial (2021) (1)
Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model (2020) (1)
Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial (2022) (1)
Structure-Activity Relationships of β-D-(2S,5R)- and α-D-( 2S,5S)-1,3-Oxathiolanyl Nucleosides as Potential Anti-HIV Agents. (1993) (1)
DrugCombinations forTreatment ofMiceInfected with Acyclovir-Resistant HerpesSimplex Virus (1987) (1)
Correction for Sohl et al., Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ (2016) (1)
cis-1-Benzoyl-2-(2-benzyloxy-5-chlorophenyl)-4-chloropyrrolidine-2-carbonitrile (2007) (1)
Variation of Human Immunodeficiency Virus Type-1 Reverse Transcriptase within the Simian Immunodeficiency Virus Genome of RT-SHIV (2014) (1)
Mechanism of action of HBV capsid assembly modulators predicted from binding to early assembly intermediates (2020) (1)
antiviral therapy using thiazine based dyes and xanthene. (1990) (1)
A General Synthetic Method of 5‐Carboranyluracil Nucleosides with Potential Antiviral Activity and Use in Neutron Capture Therapy. (1998) (1)
A new oxygen modification cyclooctaoxygen binds to nucleic acids as sodium crown complex (2016) (1)
TREM2+ and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques (2023) (1)
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al (2020) (1)
SYNTHESIS AND BIOLOGICAL ACTIVITIES OF 5-(HYDROXYMETHYL, AZIDOMETHYL, OR AMINOMETHYL)-2′-DEOXYURIDINE AND RELATED 5′-SUBSTITUTED ANALOGS (1980) (1)
Synthesis, structure-activity relationships, and mechanism of drug resistance of D- and L-beta-3'-fluoro-2',3'-unsaturated-4'-thionucleosides as anti-HIV agents. (2004) (1)
Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. (2014) (1)
Moving Fast Toward Hepatitis B Virus Elimination. (2021) (1)
Method and compositions of synthesis bch-189 and related compounds. (1991) (1)
Sonication-Assisted Synthesis of (E)-2-Methyl-but-2-enyl Nucleoside Phosphonate Prodrugs. (2016) (1)
Targeting JAK-STAT Pathway for Various Inflammatory Diseases and Viral Infections (2020) (1)
Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice (2018) (1)
Response to Correspondence: Baricitinib as Treatment of COVID-19 Friend or Foe of the Pancreas? Cerda-Contreras et.al. (2020) (1)
Synthesis and antiviral evaluation of fluorinated acyclo-nucleosides and their phosphoramidates (2017) (1)
Anti-respiratory syncytial virus activity of selected polyoxometalates (1995) (1)
Frontiers in Drug Development for Viral Hepatitis The 6th biennial meeting in this HEP DART series (2005) (1)
Synthesis of Novel 3′‐C‐Methyl‐apionucleosides: An Asymmetric Construction of a Quaternary Carbon by Claisen Rearrangement. (2000) (1)
Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys. (1999) (1)
N-O Diheterocyclic Nucleosides: Synthesis of 2′-N-Methyl-3′- hydroxymethyl-1′,2′-isoxazolidinylthymidine. (1996) (1)
1-(Ethoxymethyl)-6-(phenylselenyl)-5-ethyl uracil: a nucleoside analog (1999) (1)
7-Deaza Neplanocin Analogs Inhibit Hepatitis C Virus (HCV) in Vitro (2007) (1)
Lessons Learned from In-Person Conferences in the Times of COVID-19 (2022) (1)
Synthesis and anti-HIV Activity of Dihydroisoxazole 6-Chloropurine and Adenine. (1996) (1)
Laboratory safety considerations. (2000) (1)
The Human Herpesviruses - An Interdisciplinary (1982) (1)
Diastereoselective Synthesis of 2′-Dihalopyrimidine Ribonucleoside Inhibitors of Hepatitis C Virus Replication (2021) (1)
Brain Targeting of Anti‐HIV Nucleosides: Synthesis and in vitro and in vivo Studies of Dihydropyridine Derivatives of 3′‐Azido‐2′,3′‐ dideoxyuridine and 3′‐Azido‐3′‐deoxythymidine. (1991) (1)
Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase (2020) (1)
2′,3′-Didehydro-2′,3′-dideoxynucleosides Are Degraded to Furfuryl Alcohol under Acidic Conditions. (2004) (1)
Intracellular Metabolism of b - L -2 9 ,3 9 -Dideoxyadenosine: Relevance to Its Limited Antiviral Activity (2000) (1)
Chapter 21 – Antiviral β-L-nucleosides specific for hepatitis B virus infection (2003) (1)
Hepatitis B virus transgenic severe combined immunodeficient mouse model of acute and chronic liver disease. (2004) (1)
Synthesis of 2-Deoxy-2-fluoro-2-C-methyl-D-ribofuranoses. (2007) (1)
Design, antihuman immunodeficiency activity and molecular docking studies of synthesized 2-aryl and 2-pyrimidinyl pyrrolidines (2020) (1)
High-performance liquid chromatographic determination of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane, and their metabolite (-)-beta-D-dioxolane guanine in monkey serum, urine and cerebrospinal fluid. (1997) (0)
Modifications of Nucleosides, Nucleotides, and Nucleic Acids using Huisgen's [3+2] Azide–Alkyne Cycloaddition: Opening Pandora's Box (2016) (0)
Antiviral 2-hydroxymethyl-5- (5-fluorcytosin-1-yl) -1,3-oxatiolan and also its resolution (1993) (0)
Emtricitabine (2003) (0)
[571] COMBINATIONS OF 2′-METHYLCYTIDINE ANALOGS WITH INTERFERON ALPHA-2b LEAD TO SYNERGISTIC INHIBITION OF HEPATITIS C VIRUS REPLICATION IN A REPLICON SYSTEM (2007) (0)
Synthesis of 2′,3′-Dideoxy-2′-fluoro-L-threo-pentofuranosyl Nucleosides as Potential Antiviral Agents. (2000) (0)
Anti-HIV activity of new pyrazolobenzothiazine 5,5-dioxide-based acetohydrazides (2015) (0)
Identification of Botanical Viral Entry Inhibitors for SARS‐CoV‐2 (2022) (0)
Anti-HIV-1 and cytotoxicity studies of piperidyl-thienyl chalcones and their 2-pyrazoline derivatives (2011) (0)
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir (2022) (0)
Simian Immunodeficiency Virus (SIV) Persistence in Antiretroviral Therapy (ART)-Treated Infant Rhesus Macaques (2016) (0)
Synthesis and evaluation of 2 0-substituted cyclobutyl nucleosides and nucleotides as potential anti-HIV agents (2007) (0)
Phenylselenenyl‐ and Phenylthio‐Substituted Pyrimidines as Inhibitors of Dihydrouracil Dehydrogenase and Uridine Phosphorylase. (1994) (0)
1,3-oxathiolane and a process for its preparation (2003) (0)
Selenium Nucleophiles for the Preparation of Antiviral Nucleosides. (2010) (0)
anti‐Human Immunodeficiency Virus Type‐1 (HIV‐1) and anti‐Hepatitis B Virus (HBV) Activities of (2,3‐Dideoxy‐2‐fluoro‐β‐L‐threo‐ pentofuranosyl)nucleosides. (1995) (0)
Compounds 2 'or 3'-deoxy- and 2', 3'-dideoxy-beta-L-pentofuranonucleosides, preparation method and therapeutic application, especially anti-viral. (1993) (0)
Enriched zones of embedded ribonucleotides are associated with DNA replication and coding sequences in the human mitochondrial genome (2023) (0)
New Unnatural L-Nucleoside Enantiomers: From Their Stereospecific Synthesis to Their Biological Activities. (1998) (0)
Preclinical Development of β-D-5- o -Carboranyl-2′-Deoxyuridine (D-CDU) for the Treatment of Malignant Brain Tumors (2001) (0)
Structural insights into the recognition of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) by HIV-1 reverse transcriptase: First crystal structures with RT and the active triphosphate forms of lamivudine and emtricitabine. (2019) (0)
Antiviral Activity of 5-Ethyl-2′-Deoxyuridine against Herpes Simplex Viruses in Cell Culture, Mice, and Guinea Pigs (1985) (0)
A process for the beta-2-hydroxymethyl-5- (5-fluoro-cytosin-1-yl) -1,3-oxathiolane (2006) (0)
Activities of1-(2-Deoxy-2-flu oro-r-D-arabinof uranosyl)-5- iodocytosine andItsMetabolites against HerpesSimplex Virus Types1and2inCellCulture andinMiceInfected Intracerebrally withHerpesSimplex VirusType2t (1986) (0)
Synthesis and Antiviral Activities of Enantiomeric 1‐[2‐(Hydroxymethyl)cyclopropyl]methyl Nucleosides. (2000) (0)
Novel cell culture 3D model for HBV/HIV co-infection and antiviral evaluation (2020) (0)
POTENTIAL-KONTROLLIERTE ANODISCHE OX. VON 4-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXY-ISOCHROMAN-3-ON (1972) (0)
Salts of amides of (-) cis 5-fluoro-2'-3'-thiacytidine dedoxi useful for the treatment of hepatitis b. (1992) (0)
Enhanced enzyme kinetics of reverse transcriptase variants cloned from animals infected with SIVmac239 lacking viral protein X. (2020) (0)
5',9-Anhydro-3-(β-D-ribofuranosyl)purine nucleoside analogues as potential anti-HCV agents (2005) (0)
Mechanism of Anti-Human Immunodeﬁciency Virus Activity of (cid:2) - D -6-Cyclopropylamino-2 (cid:3) ,3 (cid:3) -Didehydro-2 (cid:3) ,3 (cid:3) -Dideoxyguanosine (2005) (0)
Antiviral and Cellular Metabolism Interactions 4 between Dexelvucitabine and Lamivudine 5 6 (2007) (0)
In silico design of a novel nucleotide antiviral agent by free energy perturbation (2022) (0)
Using real time PCR to determine anti-HIV-1 activity and mitochondrial toxicity of nucleoside analogs (2001) (0)
Unexpected Formation of Novel Butenolides by Thermolysis of o-Carboranyl Substituted Cyclobutenones. (1998) (0)
by its 5'-triphosphate. immunodeficiency virus reverse transcriptases simian and preferential inhibition of human and Phosphorylation of 3'-azido-2',3'-dideoxyuridine (2013) (0)
Activite antivirale et resolution de 2-hydroxymethyl-5-5-fluorocytosine-1-yl-1,3-oxathiolane (1992) (0)
Asymmetric synthesis of 1,3-Dioxolane Nucleosides and their anti-HIV activities (1991) (0)
Inorganic compounds and the treatment of aids (1989) (0)
Antiviral agents. (1983) (0)
1 Abundant Non-Canonical dUTP Found in Primary Human Macrophages Drives Its Frequent Incorporation by Human Immunodeficiency Virus Type 1 Reverse Transcriptase (2011) (0)
Multivariant surface quasispecies in a hepatitis B virus chronically infected individual with concomitant and continually positive surface antigen and anti-HBS biomarkers (2020) (0)
Nucleosides. Part 136. Synthesis and Antiviral Effects of Several 1‐(2‐Deoxy‐2‐fluoro‐β‐D‐arabinofuranosyl)‐5‐alkyluracils. (1986) (0)
Synthesis, anti-HIV and anti-HBV activities of novel oxaselenolane nucleosides (1997) (0)
Synthesis of Novel N4-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents (2022) (0)
Single-amplicon, multiplex real-time RT-PCR with tiled probes to detect SARS-CoV-2 <italic toggle='yes'>spike</italic> mutations associated with variants of concern (2021) (0)
Development of carboranyl pyrimidines and nucleoside derivatives for the treatment of prostate cancer (2002) (0)
Synthesis, Antiviral Activity, Cytotoxicity and Cellular Pharmacology of L‐3′‐Azido‐2′,3′‐dideoxypurine Nucleosides. (2012) (0)
Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective (2023) (0)
Salts and amides of the (-) cis-5-fluoro-2'-deoxy-thiacytidine which are suitable for the treatment of hepatitis B (1992) (0)
Process for preparing nucleosides beta-d - (-) - dioxolane enantiomerically pure. (1991) (0)
University of Groningen Anti-Human Immunodeficiency Virus, Toxicity in Cell Culture, and Tolerance in Mammals of a Water-Soluble Fullerene Schinazi, (2001) (0)
Host SAMHD1 protein restricts endogenous reverse transcription of HIV-1 in nondividing macrophages (2018) (0)
736 NOVEL EFFECTOR OF HBV CAPSID ASSEMBLY REDUCES THE ACTIVITY OF cccDNA AND INTERACTS SYNERGISTICALLY WITH NUCLEOSIDE ANALOGS IN THE HUMAN HEPATOCYTES (2013) (0)
The Base Component of 3 (cid:1) -Azido-2 (cid:1) ,3 (cid:1) -Dideoxynucleosides Inﬂuences Resistance Mutations Selected in HIV-1 Reverse Transcriptase (cid:1) (2011) (0)
In vitro influenza virus-inhibitory effects of a series of germanium- orsilicon-centered polyoxometalates (1997) (0)
Resistance Mechanisms to HIV-1 Nucleoside Reverse Transcriptase Inhibitors (2017) (0)
Screening of new antivirals for wild-type hepatitis B virus and three lamivudine-resistant mutants (1999) (0)
Discovery of a 2′-Fluoro,2′-Bromouridine Phosphoramidate Prodrug Exhibiting Anti-Yellow Fever Virus Activity in Culture and in Mice (2022) (0)
Comparison of anti-HBV activity of beta-D- and beta-L-DDA-5'monophosphate prodrugs and effectiveness in combination with lamivudine. (1999) (0)
Elevation of Intracellular dNTP Levels: A Mechanistic Role of SAMHD1 Cancer Mutations (2021) (0)
Synthesis and Biological Activity of 5′,9-Anhydro-3-purine-isonucleosides as Potential anti-Hepatitis C Virus Agents. (2007) (0)
Using 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B (1992) (0)
Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies (2023) (0)
O.185 Drug-drug interaction between clevudine in combination with telbivudine or 3TC in human liver cells (2006) (0)
Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2 (2022) (0)
HIV latency reversal research and the potential effects on the central nervous system: is concern warranted? (2016) (0)
Method of useful beta-2-hydroxymethyl-5- (5-fluorocytosin-1-yl) preparing a therapeutically -1,3-oxathiolane (2005) (0)
CRYSTAL STRUCTURE AND ANTI-HERPES SIMPLEX VIRUS ACTIVITY OF 2,2′-ANHYDRO-1-β-D-ARABINOFURANOSYLTHYMINE (1983) (0)
Synthesis of 2′,3′-Dideoxy-3′-fluoro-L-ribonucleosides as Potential Antiviral Agents from D-Sorbitol. (2000) (0)
New Classes of Fluorinated L‐Nucleosides; Synthesis and Antiviral Activity (1999) (0)
Deoxyuridine Neutron Capture Therapy ′-Carboranyl-2 o-5-β Treatment of Isografted 9 L Rat Brain Tumors with Updated (2000) (0)
dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages (2014) (0)
MOLECULAR BASIS FOR SERENDIPITOUS DEVELOPMENT OF ANTIVIRAL AND ANTICANCER AMINONUCLEOSIDES (1979) (0)
Synthesis and Evaluation of 3′-Azido-2′,3′-dideoxypurine Nucleosides as Inhibitors of Human Immunodeficiency Virus. (2010) (0)
Synthesis of lipophilic tethered 5-O-carboranyl-2'-deoxyuridines (2007) (0)
The Royal Society o-2 0-deoxy-a-nucleosides : synthesis , characterization and biological activity † (2020) (0)
192 Synthesis and biological evaluation of D-(2S) and L-(2R)-1,3-oxathiolanyl- and D-(2R)-and L-(2S)-1,3-dioxolanyl-nucleoside as anti-HIV and anti-HBV agents (1993) (0)
AN IMPROVED SYNTHESIS OF 6H-PYRIDO(4,3-B)CARBAZOLE DERIVATIVES (1975) (0)
William H Prusoff Dies at 90 – A Renaissance Man that Revolutionized the Treatment of Herpesviruses and HIV (2011) (0)
Design, antihuman immunodeficiency activity and molecular docking studies of synthesized 2-aryl and 2-pyrimidinyl pyrrolidines (2020) (0)
Abundant Non-Canonical dUTP Found in Primary Human Macrophages Drives Its Frequent Incorporation by Human Immunodeficiency Virus Type 1 Reverse Transcriptase (2011) (0)
Synthesis of Six-Membered Nucleoside Analogues. Part 1. Pyrimidine Nucleosides Based on the 1,3-Dioxane Ring System. (1997) (0)
Effect ofCombinations ofAcyclovir withVidarabine orIts 5'-Monophosphate onHerpes Simplex Viruses inCellCulture andinMice (1982) (0)
An Efficient Route to β-D-Isoxazolidinyl Nucleosides via Diastereoselective Michael Addition of Hydroxylamine to Unsaturated Esters. (1998) (0)
SYNTHESIS AND BIOLOGICAL ACTIVITIES OF SOME URONIC ACIDS, URONATES, URONAMIDES, AND URONONITRILES OF PYRIMIDINE NUCLEOSIDES (1979) (0)
N 4-Hydroxycytosine Dioxolane Nucleosides and Their Activity Against Hepatitis B Virus (2005) (0)
Acyclic Analogues of 3′-Azido-3′-deoxythymidine as Potential Antiviral Agents. Nucleoside Synthesis by Michael Addition. (1989) (0)
Pyrimidines. Part 67. Synthesis and Antihuman Immunodeficiency Virus ( HIV-1) Activity of 3′-Deoxy-3′-(triazol-1-yl)thymidines and 2′,3′- Dideoxy-3′-(triazol-1-yl)uridines, and Inhibition of Reverse Transcriptase by Their 5′-Triphosphates. (1991) (0)
Subcellular Localization of a Boronated Nucleoside Using Ion Microscopy (1996) (0)
Liver Cells (0)
Synthesis of Enantiomerically Pure D‐FDOC, an anti‐HIV Agent. (2005) (0)
compared with azithromycin for the treatment of uncomplicated genital (2014) (0)
Reply to Cerda-Contreras, et al. (2020) (0)
1-(4-Methylphenyl)-5-oxo-2-phenylpyrrolidine-2-carboxamide–methanol (1/1) (2007) (0)
Cellular and Molecular Events Leading to Mitochondrial Toxicity of 1-( 2-Deoxy-2-Fluoro-1-, fD-Arabinofuranosyl )-5-lodouracil in Human Liver Cells (2013) (0)
Nucleoside Antiviral Agents for HCV (2020) (0)
Process for the preparation of therapeutically useful beta-2-hydroxymethyl-5- (5-fluorocytosin-1-yl) -1,3-oxathiolane enantiomers (1993) (0)
Synthesis of (3.3.0) Bicyclic Isoxazolidinyl Nucleosides. (1996) (0)
Pharmacokinetics of3'-Azido-3'-Deox ythymidine andItsCatabolites andInteractions withProbenecid inRhesusMonkeys (1991) (0)
HBV REPLICATION CYCLE AND THERAPEUTIC TARGETS (0)
Effects of HIV‐1 on Endothelial Gene Expression (2008) (0)
Novel Capsid Assembly Effectors Inhibit Hbv Cccdna Formation in an Hbeag Reporter Cell-Based Assay (2016) (0)
Synthesis and anti-HIV-1 screening of novel N′-(1-(aryl)ethylidene)-2-(5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-4(1H)-yl)acetohydrazides (2013) (0)
Inhibition ofHumanImmunodeficiency Virus Type1Reverse Transcriptase bythe5'-Triphosphate Enantiomers ofCytidine Analogs (1994) (0)
Anti-human immunodeficiency activity of novel 2-arylpyrrolidine analogs (2016) (0)
Inactivation of SARS Coronavirus 2 and COVID-19 patient samples for contemporary immunology and metabolomics studies (2021) (0)
Combinations ofIsoprinosine and3'-Azido-3'-Deox ythymidine in Lymphocytes Infected withHumanImmunodeficiency Virus Type1 (1988) (0)
ENANTIOMERICALLY PURE β-D-DIOXOLANE-NUCLEOSIDE (1993) (0)
Pharmacokinetics of the Antiviral Agent bD-2 9 , 3 9-Didehydro-2 9 , 3 9-Dideoxy-5-Fluorocytidine in Rhesus Monkeys (1999) (0)
Pediatric HIV Cure: A Rhesus Macaque Model (2015) (0)
The boron-neutron capture agent beta-D-5-o-carboranyl-2'-deoxyuridine accumulates preferentially in dividing brain tumor cells. (2005) (0)
Pharmacokinetic studies of dipalmitoyl-phosphatidyl-2′,3′-dideoxy-3′-thiacytidine (DPP-3TC) in rodents (1997) (0)
Effect of induced dNTP pool imbalance on HIV-1 reverse transcription in macrophages (2019) (0)
Erratum to: Synthesis and anti-HIV-1 screening of novel N′-(1-(aryl)ethylidene)-2-(5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-4(1H)-yl)acetohydrazides (2013) (0)
Pattern of resistance against AZT-resistant HIV-1 in human peripheral blood mononuclear cells (1991) (0)
Novel inhibitors of inosine monophosphate dehydrogenase (IMPDH) (2002) (0)
Non-HIV-1 CD4+ lymphocyte depletion in a patient with an acquired immunodeficiency syndrome of unknown etiology. (1993) (0)
Pharmacodynamics of (−)-β-2′,3′-Dideoxy-3′-Thiacytidine in Chronically Virus-Infected Woodchucks Compared to Its Pharmacodynamics in Humans (1998) (0)
Detection of respiratory syncytial virus by quantitative real time PCR (2002) (0)
SYNTHESIS OF 2',3'-ÉPIMINO-2',3'-DIDEOXYPYRIMIDINE A NUCLEOSIDE DERIVATIVE INTO LYXO CONFIGURATION (2008) (0)
Beta-D-dioxolane-nucleosides enantiomerically pure. (1993) (0)
5-substituted 2'-fluoro-arabinonucleosides as potential antiviral agents. (1987) (0)
Method 2 ', 3'-dideoxy-3'-thia-pyrimidine nucleoside comprising a mixture of isomers for the preparation of (2005) (0)
Synthesis and Biological Evaluation of New Enantiomers of 5‐o‐Carboranyl Pyrimidine Nucleosides (1999) (0)
Safety, Pharmacokinetics, and Efﬁcacy of ( (cid:1) / (cid:2) )- (cid:3) -2 (cid:4) ,3 (cid:4) -Dideoxy-5-Fluoro-3 (cid:4) -Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naı¨ve Human Immunodeﬁciency Virus-Infected Patients (2005) (0)
2'-fluoro nucleosides (1999) (0)
ANTIVIRAL AND ANTINEOPLASTIC ACTIVITIES OF PYRIMIDINE ARABINOSYL NUCLEOSIDES AND THEIR 5′-AMINO DERIVATIVES (1980) (0)
Abstract B38: Epigenetic effects of viral proteins on global levels of 5-hydroxymethylcytosine in HBV- and HCV-associated hepatocellular carcinoma in mice (2013) (0)
Synthesis, molecular docking and antiviral screening of novel N′-substitutedbenzylidene-2-(4-methyl-5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-1(4H)-yl)acetohydrazides (2013) (0)
Compounds 2 'or 3'-deoxy and 2', 3'-dideoxy-beta-L-pentofuranonucleoside, method of preparation and therapeutic use, including anti-viral. (1993) (0)
Production of medicinal composition using thiazine dye or xanthene dye (1995) (0)
NEW INHIBITORS OF uridine (UrdPase) AND dihydrouracil (DHUDase) (1994) (0)
2′‐Fluoro‐4′‐thio‐2′,3′‐unsaturated Nucleosides: anti‐HIV Activity, Resistance Profile, and Molecular Modeling Studies (2004) (0)
Model Supporting High Levels of HBV Replication (2012) (0)
Synthesis and anti-hepatitis C virus activity of nucleoside derivatives of N3, 5'-anhydro-4-(beta-D-ribofuranosyl)-8-aza-purin-2-ones. (2005) (0)
Cellular Innate Immunity Activation Induced by Genetic Loss of Aicardi Goutieres Syndrome Protein Suppresses SARS-CoV-2 Replication (2020) (0)
Polybrominated Phenolics from Lendenfeldia dendyi with Antibacterial, Antifungal and Anti-HIV Activities (2010) (0)
Pharmacokinetics of the Anti-Human Immunodeﬁciency Virus Agent 1-( (cid:2) - D -Dioxolane)Thymine in Rhesus Monkeys (cid:1) † (2007) (0)
Kinetic variations between reverse transcriptases of viral protein X coding and noncoding lentiviruses (2014) (0)
A process for preparing Enantiomerically pure beta-D-dioxolane-nucleosides (1991) (0)
CD81 receptor expression in human cells: Implications for HCV therapeutics (2003) (0)
Synthesis of novel pyrazolobenzothiazine 5,5-dioxide derivatives as potent anti-HIV-1 agents (2013) (0)
2 'or 3' -deoxy- and 2 'dideoxy-beta-L-pentafuranonukleoside, methods of making and use in therapy, in particular as antiviral agents (1994) (0)
Synthesis and anti-HCV activity of N9,5'-cyclo-3-(beta-D-ribofuranosyl)-8-azapurin-2-one derivatives. (2005) (0)
1168 BL-8030: A NOVEL, POTENT, SELECTIVE, ORALLY AVAILABLE INHIBITOR OF HEPATITIS C VIRUS NS3/4A PROTEASE (2013) (0)
Ne wManzamin eAlkaloid swit hActivit yagains tInfectiou san dTropical Parasiti cDisease sfro ma nIndonesia nSponge (2003) (0)
1-Benzyl-2-(1H-indol-3-yl)-5-oxopyrrolidine-2-carbonitrile (2008) (0)
Asymmetric Synthesis of Enantiomerically Pure (-)-(1′R,4′R)- Dioxolanethymine and Its Anti-HIV Activity. (1992) (0)
Process for the cis-FTC to separate the enantiomers (2003) (0)
Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro (2019) (0)
Ribonucleotide incorporation in yeast genomic DNA shows preference for cytosine and guanosine preceded by deoxyadenosine (2020) (0)
Synthesis and activity of human immunodeficiency virus and hepatitis b nucleoside 1,3-oxaselenolane. (1998) (0)
The Synthesis and anti‐HIV Activity of Pyrimidine Dioxolanyl Nucleosides. (1993) (0)
$G(b)-L-2'-DEOXY-NUCLEOSIDES UTILISES DANS LE TRAITEMENT DE L'INFECTION PAR VIH (1999) (0)
Editors & Editorial Board (2010) (0)
Synthesis and Anti-HIV-1 Reverse Transcriptase Activity of Triphosphates of Penciclovir and β-D-Dioxolane-Guanine (1996) (0)
Carboranyl Nucleosides & Oligonucleotides for Neutron Capture Therapy Final Report (2004) (0)
Synthesis and Biological Activity of 5-Phenylseleneny1-Substituted Pyrimidine Nucleosides. (1986) (0)
HEPATITIS B FORUM NEXT STEPS IN TREATING PATIENTS WITH CHRONIC HEPATITIS B: CAN WE CURE THIS DISEASE? (2014) (0)
Salts and amides of (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine suitable for the treatment of hepatitis B (1992) (0)
From D- to L-Nucleoside Analogues as Antiviral Agents (2000) (0)
Synthesis of Enantiomerically Pure Cyclopropyl Carbocyclic Nucleosides. (1994) (0)
A pioneer in antiviral drug discovery and development: Commemorating John Martin-Review (2022) (0)
Using triphosphate (r) -penciclovir for the manufacture of a medicament for the treatment of viral diseases. (1996) (0)
Synthesis of Dihydroisoxazole Nucleoside and Nucleotide Analogues. (2010) (0)
Study Design and Interventions (2008) (0)
A Completely Diastereoselective Electrophilic Fluorination of a Chiral, Noncarbohydrate Sugar Ring Precursor: Application to the Synthesis of Several Novel 2′-Fluoronucleosides. (1998) (0)
Pharmacokinetics of beta-D-2,3-didehydro-2,3-dideoxy-5-fluorocytidine in rhesus monkeys (1998) (0)
Title : TREM 2 + and interstitial macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques (2021) (0)
Chemical approaches for treating HIV and hepatitis B infections (1997) (0)
Synthesis of Dodeca(Thymidine Phosphate) Containing (o-Carboran-1-yl)Methylphosphonate Internucleotide Linkage (1996) (0)
Anti-HIV-1 screening of (2E)-3-(2-chloro-6-methyl/methoxyquinolin-3-yl)-1-(aryl)prop-2-en-1-ones (2013) (0)
Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2 (cid:2) -Deoxy-2 (cid:2) -Fluorocytidine (2004) (0)
Synthesis of 4′-Substituted Carbocyclic Uracil Derivatives and Their Monophosphate Prodrugs as Potential Antiviral Agents (2023) (0)
2.4A resolution structure of human Norovirus GII.4 protease (2018) (0)
An ACE2-IgG4 Fc Fusion Protein Demonstrates Strong Binding to All Tested SARS-CoV-2 Variants and Reduced Lung Inflammation in Animal Models of SARS-CoV-2 and Influenza (2022) (0)
Carboranyl Oligonucleotides for Neutron Capture Therapy Final Report (2004) (0)
Selective Inhibition ofHumanImmunodeficiency VirusType1 Replication bythe(-)butNotthe(+)Enantiomer ofGossypol (1989) (0)
Correction for Mavigner et al., “Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques” (2019) (0)
vitro. selective inhibitors of hepatitis B virus in beta-2',3'-dideoxycytidine analogs are Pure nucleoside enantiomers of (2014) (0)
Synthesis of Novel Isoxazolinyl Substituted Imidazo[1,2-a]pyridine C-Nucleoside Analogues. (1999) (0)
Nucleosides. Part 139. Synthesis and Anticytomegalovirus and Antiherpes Simplex Virus Activity of 5′-Modified Analogues of 2′-Fluoroarabinosylpyrimidine Nucleosides. (1987) (0)

This paper list is powered by the following services:

Other Resources About Raymond F. Schinazi

en.wikipedia.org

What Schools Are Affiliated With Raymond F. Schinazi?

Raymond F. Schinazi is affiliated with the following schools: